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ABSTRACT
Metallothionein Gene Expression in Human Breast Cancer
Volkan Gurel
Metallothioneins (MT) are a family of low molecular weight (6 kDa) cysteine rich proteins
that participate in a variety of functions such as detoxification of heavy metals and
homeostasis of essential metals. They can also act as scavengers of free radicals. MT-1 and
2 isoforms are ubiquitously expressed, whereas the expression of the third isoform is
limited to the neural tissue. In the PC-3 prostate cancer cell line, MT-3 expression has been
shown to inhibit cell growth and increase drug resistance. The goal of the present study
was to determine if MT-3 overexpression would influence the growth of human breast
cancer cell lines. To determine this, the coding sequence of the MT-3 gene was stably
transfected into 2 estrogen receptor positive (MCF-7 and T-47D) and 2 estrogen receptor
negative cell lines (Hs578T and MDA-MB-231) having no basal expression of MT-3. Cell
growth was determined by counting DAPI-stained nuclei, cadmium resistance by the
colony formation assay, MT mRNA expression by RT-PCR, and MT protein by immunoblot. It was demonstrated that MCF-7 and Hs578T cells that overexpress the MT-3 gene
are growth inhibited compared to untransfected cells. In contrast, T-47D and MDA-MB231 cells that overexpress MT-3 were not growth inhibited. Stable transfection of the MT1E gene had no effect on the growth of any of the 4 cell lines. It was also demonstrated that
the overexpression of both MT-3 and MT-1E only increased the resistance of MCF-7 cells
to Cd+2. In all instances, stable transfection of the MT-3 or MT-1E gene had no effect on
the expression of the other MT isoforms. The study shows that MT-3 can influence the
growth of some breast cancer cell lines.
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INTRODUCTION AND REVIEW OF LITERATURE

1

Breast cancer currently accounts for 20% of all female cancers worldwide and is the most
frequent malignancy occurring in women. In Western Europe and North America, one in every
eight or nine women will develop the disease. Inheritance of high penetrance susceptibility
genes, such as BRCA1 and BRCA2, account for only 5% of breast cancer cases and factors
responsible for the other 95% remain obscure [1]. A significant proportion of sporadic breast
cancers contain point mutations clustered within exons 5-8 of the P53 gene, and this mutational
spectrum suggests the occurrence of xenobiotic-induced mutagenic events in some cases [2].

The only environmental exposure proven to induce breast cancer is ionizing radiation [3]. Total
cumulative exposure to estrogen may play a role in breast cancer incidence and is consistent with
nulliparity, late age at first pregnancy, early menarch and late menopause as weak factors [4].
However, estrogens probably act as tumor and growth promoters rather than as complete
carcinogens but this is not a view that is universally accepted [5]. A correlation between alcohol
intake and breast cancer incidence amongst individuals lacking both the glutathionein Stransferase (GST)M1 and GSTT1 genes has been reported [6]. However, different patterns of
alcohol intake make it difficult to quantify the importance of this risk factor [7]. In addition, it is
also possible that consumption of well-done meats may correlate with an increased risk of breast
cancer [8]. So far, classic epidemiological studies have failed to highlight a dominant risk factor
that could account for sporadic breast cancer incidence and investigations into the relationship of
risk to gene-environment interactions are still in their infancy [9]

There is a sufficient, although not extensive, literature base to support an examination of the
possible relationship between Cd+2 and metallothionein protein in human breast cancer. A study
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from Finland that defines an association between human breast concentrations of Cd+2 and breast
cancer is very supportive that Cd+2 can have a role in the development and progression of breast
cancer [10]. There are also several reports that indicate that Cd+2 can act like an environmental
estrogen. The first of these demonstrated that Cd+2 increased the growth rate of MCF-7 cells 5.6
fold but was without effect on MDA-MB-231 cells [11]. The overall conclusion of this study was
that Cd+2 mimicked the effect of estradiol in the estrogen-responsive MCF-7 cells. In addition to
the effects on MCF-7 cell growth, treatment with Cd+2 resulted in an increase in the steady state
levels of progesterone receptor, pS2, and catepsin D, and a decrease in the steady state level of
estrogen receptor α (ER-α). The changes in the steady state levels of mRNA and protein of these
genes were due to changes in transcription as they were blocked by the antiestrogen, ICI-164,
384. Transfection assays also demonstrated that the effects of Cd+2 were mediated by ER-α.
These studies were extended to probe the mechanism by which Cd+2 activated ER-α [12]. The
result of this study demonstrated that low concentrations of Cd+2 activated ER-α through an
interaction with the hormone binding domain of the receptor. The interaction of Cd+2 with the
receptor was shown to involve several amino acids into the hormone binding domain and thereby
activate the receptor. It is important to note that in neither study were effects of Cd+2 influenced
or mimicked by Zn+2.

Since it is highly likely that intracellular bioavalibity of Cd+2 to ER-α is regulated by the breast
MT pool, one can hypothesize that expression of MT may be a major intracellular regulatory
determinant of Cd+2 stimulation of the ER-α. With the above in mind, it is surprising that the
relationship between MT and Cd+2 has not been explored in breast cancer.
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Metallothioneins:
Metallothioneins (MTs) were first discovered from horse kidney by Morgoshes & Vallee in 1957
and was subsequently purified and characterized by Kägi and Vallee [13]. This discovery
marked a field of research focused on the study of a low molecular weight polypeptide
superfamily, the metallothioneins. MTs are cysteine rich, low molecular weight (6-7 kDa),
nonenzymatic, intracellular proteins ubiquitous in all eukaryotes (often encoded multiple copy
genes) as well as some prokaryotes [14, 15]. In the mouse, there are four MT genes (MT-1, 2, 3
and 4) that reside in a 50 kb region on chromosome 8, whereas in the humans in addition to the
four genes, numerous isoforms of MT-1 are clustered on chromosome 16q13 (Figure I) [16, 17].
Human MT proteins are encoded by 10 genes: MT-1A, MT-1B, MT-1E, MT-1F, MT-1G, MT1H, MT-1X, MT-2A, MT-3 and MT-4. In addition to these ten functional isoforms, there are
seven non-functional isoforms: MT-1C, MT-1D, MT-1I, MT-1J, MT-1K, MT-1L and MT-2B
[18]. The MT-1 and MT-2 isoforms, which differ by only a single negative charge, are the most
widely expressed isoforms in different tissues and are the best studied (Figure I.)
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Figure 1. Location of human metallothionein isoforms with respect to each other on chromosome 8.

Structure:
MT harbors high metal content. Mammalian MTs contain 20 cysteine residues, which are central
to the binding of metals. The stoichiometry is such that there are 7 bivalent ions for every 20
cysteines, which form metal thiolate complexes, therefore enabling the MT to bind between 7-10
atoms of metal/mol MT in a two domain structure [18]. The protein has the shape of a dumbbell
and envelops the metals that it contains in two separate domains in a manner that effectively
shields them from the environment. It is most remarkable that the metals are arranged in a cluster
structure unique to biology. In one cluster (N-terminal α-domain), four metal atoms are bound to
11 cycteines, five of which bridge the metals; the other (C-terminal β-domain) has three metal
atoms and nine cysteines with three bridges (Figure II) [19]. Zinc is bound extremely tightly (KD
about 10-13 M).
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Figure 2. Schematic drawing of zinc thiolate clusters in MT based on both x-ray diffraction and NMR spectroscopy
data. (Adopted from Edmont H. Fischer and Earl W. Davie, Recent excitement regarding metallothionein, Proc.
Natl. Acad. Sci. USA, Vol. 95, pp 3334, 1998.)

Intramolecular metal linkages can stabilize the MT protein secondary structure, therefore, loss of
metal can causes structural changes, rendering the polypeptide chain vulnerable to proteolysis
[20]. Stability is also influenced by the nature of the metals bound to MT. Predominantly, Zn+2,
but sometimes also Cu+2 are bound in vivo under physiological conditions. However, several less
abundant transition metals, such as Cd+2, Bi+3, Pt+2, Ag+ and Hg+2 also bind eagerly to MT in
vitro. The binding affinity of different metals for MT varies considerably and has the following
order: Zn+2<Pb+2<Cd+2<Cu+<Ag+ = Hg+2 = Bi+3, therefore making zinc readily displaceable by
other metal ions [21].

Function:
Despite the accumulation of detailed information on both the biochemical and molecular aspects
of MT structure and expression, its biological role is still not clearly understood more that 40
years after its discovery. The fact that there are multiple copies of MT genes expressed in distinct
patterns, and the relatively rapid turnover of the protein suggest that they should have important
functions. One of the proposed functions of MT is that MTs play important role in maintaining
essential metal homeostasis. Zn+2 is a physiologically important metal and the most abundant
metal bound to constitutive MT. Zn+2 provides essential structural and catalytic functions to a
variety of proteins. Zn+2 is also crucial in the regulation of gene expression because numerous
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transcription factors have “zinc finger motifs” that are maintained by Zn+2. Apo-MT
(metallothionein with no metals bound) is a Zn+2 acceptor because of the abundance of free
sulfhydryl groups and their high affinity for Zn+2. However, the sulfhydryl groups are highly
reactive, and Zn+2, although bound with high affinity, can undergo exchange reactions, which
allows Zn+2 to be transferred from MT to other proteins [22, 23, 24, 25]. The affinity of
sulfhydryl groups for Zn+2 can also make MT an efficient metal ion scavenger. This implies a
possible regulatory role of MT in the activation or inactivation of various molecular effectors.
Such a possibility was demonstrated by showing that apo-MT can chelate Zn+2 out of the
transcription factor IIIA (TFIIIA), a process that inactivates TFIIIA [26]. Therefore it is tempting
to speculate that MT might be essential for Zn+2 homeostasis by regulating Zn+2 absorption, or as
a donor of Zn+2 to various enzymes and transcription factors during development or protein
synthesis.

There is strong evidence that MTs play an important role in protection against metal toxicity. In
unicellular eukaryotes, MTs bind copper predominantly [14, 15]. Mutations that prevent MT
synthesis confer copper sensitivity, whereas excess expression of MTs confers resistance to
copper toxicity [19, 27]. In mice MT is an important protein in the cellular defense against Cd+2
toxicity and lethality, but it provides much less protection against the lethality of the other metals
such as, Zn+2, Cu+, Fe, Pb+2, Hg+2 and As [27]. Cadmium is a ubiquitous and insidious pollutant.
A by-product of zinc production by humans and a component of volcanic eruption by nature, the
element is chiefly used in the industrial plating process and can be found in products as diverse
as solder, artists' pigments, and rechargeable batteries. It is even used to absorb neutrons in the
control rods and shielding of nuclear reactors. Depending on the dose, route and duration of
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exposure, Cd+2 can cause damage to various organs including the lung, liver, kidney, bones,
testis and placenta [28, 29, 30, 31, 32, 33]. Acute exposure to Cd+2 produces hepatic, pulmonary,
and testicular injury, whereas chronic exposure results in renal and bone injury and cancer [34].
The Agency for Toxic Substances and Disease Registry (ATSDR) currently ranks Cd+2 7th on its
priority list of hazardous substances [35]. Moreover, various mammalian cell lines that can not
synthesize any MT are sensitive to cadmium toxicity whereas mice and the cells that overexpress
MT are resistant to Cd+2 [36, 37]. In fact, selection for cadmium resistance with mammalian cells
results in up to 80-fold amplification of the entire MT-locus [38]. The role of MT in Cd+2
disposition has been examined in MT-transgenic mice. In this model, MT does not inhibit
intestinal Cd2+ absorption, nor does it affect initial Cd2+ distribution to various tissues [39, 40].
However, MT decreases Cd+2 elimination through the bile and is a major factor for tissue
retention of Cd+2 [40, 41, 42]. The results of a number of studies with humans environmentally
exposed to Cd2+ demonstrated that proteinuria is the main renal injury in these subjects [43].
Because Cd+2 injures proximal tubules of kidney, an increased excretion of protein into urine is
observed.

MTs are cysteine-rich molecules. Therefore, it is reasonable to expect that sulfhydryl-rich MTs
may function in a manner similar to GSH, wherein MT provides an intracellular nucleophilic
sink to “trap” electrophiles, alkalyting agents, and free radicals [44, 45, 46]. The multiple
cysteine residues of MT can be oxidized during oxidative stress, and the subsequent release of
Zn+2 has been proposed to be important in protecting against oxidative damage [47, 48].
However, it has been difficult to demonstrate oxidation of MT in vivo. Therefore, there have
been controversial reports on the role of MT during oxidative stress.
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Gene Regulation:
A variety of stimuli such as metals, hormones, cytokines, a range of other chemicals,
inflammation and stress can induce metallothioneins. Some of these stimuli include metals,
hormones, cytokines, a range of other chemicals, inflammation, and stress [49]. The most
extensively studied of these inducers are metals and glucocorticoids, both being efficient
inducers of MT. However, both of these entities display species differences in isoform induction.
In mice, both metals and glucocorticoids, equally induce MT-1 and MT-2; in man, metals induce
all the MT isoforms whereas glucocorticoids only induce MT-2A and MT-1E [50, 51]. Thus,
human MT isoforms are regulated independently of each other whereas in mouse the MT-1 and
MT-2 isoforms are co-ordinately regulated. [49, 52]. With the exception of glucocorticoids only
metals have been shown thus far to be capable of inducing the human MT-1 isoforms. This
demonstrates the apparent simplicity of the human MT-1 promoter region compared with that of
MT-2A, which contains several enhancer regions [51]. Moreover, the induction of different
isoforms appears to be metal dependent as are the rates, extent and time course of MT mRNA
transcript accumulation [52, 53]. Considerable progress has been made in understanding the
mechanism by which metals induce MT and the way in which expression of this protein is
regulated, even though the regulation of protein expression not yet fully understood [54].

Exposure to heavy metals leads to a significant MT synthesis and this synthesis is thought to be
mediated via cis-acting DNA sequences or metal responsive elements (MREs) which are present
as multiple copies in the promoter region of all the MT genes [55, 56]. These cis-acting regions
are conserved among many diverse organisms but are not all functionally equivalent [57].
Moreover, variations in the ability of different MREs to mediate metal-activated transcription of
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MT genes have been reported [58]. For instance, of the five MREs in the mouse MT-1 promoter,
MREd appears to be the strongest enhancer of MT gene transcription [59]. In addition to MREs,
glucocorticoid response element (GRE), antioxidant response element (ARE), cyclic AMP
responsive elements, TPA-responsive elements and interferon responsive elements have also
been defined in a few MT promoters.[60, 61, 62].

Proteins which are thought to be positively acting transcription factors bind with MREs in a
metal-dependent manner during metal induction of MT [63]. Following metal exposure, various
different proteins from nuclear extracts of cells of both rodent and human origin have been
identified as possible regulators of metal mediated gene transcription [60]. These include metal
response element binding factor-I (MBF-I), zinc activated protein (ZAP), and zinc regulated
factor (ZiRF1). These proteins have different binding affinities for the various MREs. Also,
variability in binding activity with different metals has been reported. It is not clear if the binding
of these proteins is metal specific [64].

Two proteins identified from nuclear extracts of HeLa cells do affect metal-mediated MT gene
transcription. These are MREBP (MRE binding protein) that specifically binds MREs of the
human MT-2A gene and MTF-1 (MRE binding transcription factor), constitutively active zincsensitive factor. MREBP is thought to inhibit transcription, whereas MTF-1 is thought to have an
important role in the control of MT gene expression [56, 61, 65, 66].

Genes encoding human MTF-1 (hMTF-1) and the mouse MTF-1 (mMTF-1) have been cloned.
hMTF-1 is a 753 amino acid protein that shares a 93% amino acid sequence identity with
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mMTF-1, although it is 78 amino acid longer at the C terminus than mMTF-1 [67]. Each
contains six zinc fingers of the cys2-his2 type in the DNA binding domain and three different
trans-activation domains. The activity of MTF-1 is controlled via complex interdomain
interactions and by the first zinc finger, which is saturated with zinc only at higher
concentrations than the other zinc finger [68]. Therefore, inactivated MTF-1 with zinc-saturated
fingers 2 to 6 can be activated by physiological increases in zinc [69]. Since neither MT-1 nor
MT-2 gene were detectable in MTF-1 null cells even after metal exposure, this factor is essential
for both constitutive and metal induced MT expression [ 70].

MTF-1 is mainly activated by zinc. Surprisingly there is evidence suggesting that oxidative stress
also activates this transcription factor, resulting in increased binding to MREs [61, 71]. It is
possible that oxidation of cellular ligands binding zinc may release metal to activate MTF-1.
There is also evidence that hypoxia activates MT gene expression through MREs and that this
activation involves MTF-1 [72].

In resting cells, most MTF-1 localizes to cyctoplasm from which it is translocated to the nucleus
under several different stress situations [73, 74]. The finding that MTF-1 requires elevated
concentrations of zinc for strong binding to DNA suggests that MTF-1 is activated by allosteric
regulation of DNA binding via binding of metals to the transcription factor itself [65, 70, 75].
Although heavy metals readily induce metallothionein gene transcription in cultured cells, none
of them can substitute for zinc in cell-free DNA binding reaction of MTF-1 [70]. The most likely
scenario is the replacement of zinc by other heavy metals in cellular and/or extracellular zinc
storage proteins, leading to concomitant activation of MTF-1 by the released zinc. In addition,
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MTF-1 can be phosphorylated upon metal induction, as a result of the activation of a complex
kinase signaling transduction pathway which includes protein kinase C (PKC), phosphorinositol-3 kinase (PI3K), c-Jun N-terminal kinase (JNK) and a tyrosine-specific kinase [76].
(Figure 3.)

Figure 3. Schematic overview of known and inferred activation pathways and downstream functions of the metal
transcription factor MTF-1. (Adopted from Peter Lichtlen, Walter Schaffner, The “metal transcription factor” MTF1: Biological facts and medical implications. Swiss Med Wkly 131: 649, 2001.)
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The accumulation of the MT 1/2 protein as detected via immunohistochemistry has different
prognostic significance in various human tumors [77]. In tumors such as colonic and bladder
cancers, MT 1/2 overexpression is frequently associated with well differentiated and lower
histological grade tumors. Whereas in tumors such as ductal breast cancer, cervical carcinoma,
endometrial carcinoma and pancreatic carcinoma, MT overexpression appears to be
predominantly associated with more aggressive and higher-grade tumors [78, 79].

The

expression of MT was also analyzed in normal breast tissue and in variety of benign, preinvasive, and malignant breast lesions. Normal breast tissue did not stain for MT [80]. The
available information on the character and consequences of MT overexpression associated with
human cancer is presently too limited to offer complete understanding.

MT protein has been shown to be a useful prognostic and diagnostic marker in a variety of
human cancers. First and second isoform of MT protein has been documented to be
overexpressed in a sub-set of human breast cancers and that overexpression correlates to poor
prognosis. There is a strong evidence that overexpression of metallothionein isoform 3 (MT-3)
protein correlates to poor disease outcome in subset of human breast cancers [81]. The goal of
this project is to define the role of MT-1/2 and MT-3 protein in cancer progression using a cell
culture model and strengthen the potential use of these proteins in diagnosis and prognosis of
breast cancer.
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In this chapter, author will present the materials and methods used in this project. All the cell
lines utilized in experiments obtained from American Type of Culture collection. The breast cell
lines (MCF-7, MCF-10, T-47D, Hs578T and MDA-MB-231) utilized in the experiments have
been used in similar type of applications commonly. Among the five breast cell lines, MCF-10A
represent the normal immortalized breast cell line. Rest of the cell lines are well differentiated
malignant breast cancer cell lines. Gene expression of Metallothioneins and protein levels were
assesed utilizing Reverse Trancriptase Polymerase chain reaction and immunoblott analysis (dot
blot). Growth studies were initiated following a 1:10 subculture and cell counts were determined
by the automated counting of DAPI- stained nuclei. MT-3 and MT-1E coding sequence were
cloned from cultured human proximal tubule cells for the transfection studies.

Cell Culture of MCF-7, T-47D, Hs578-T, MDA-MB-231 and MCF-10A Cell Lines:

The MCF-7, T-47D, Hs578-T, MDA-MB-231 cells were obtained from American Type Culture
Collection (Rockville, MD), and grown in Dulbeco’s

Modified Eagles Medium (DMEM)

supplemented with 5% (v/v) fetal calf serum, 5 mg/ml glucose and routinely passaged at a 1:10
ratio upon attaining confluence. The MCF-10A cell line was also obtained from the American
Type Culture Collection, maintained in 1:1 mixture of Ham’s F-12 medium and DMEM
supplemented with 5% (v/v) fetal calf serum, 10 µg/ml insulin, 0.5 µg/ml hydrocortisone, 20
ng/ml epidermal growth factor, 0.1 µg/ml cholera toxin and routinely passaged at a 1:10 ratio
upon attaining confluence. The cells were kept in T75 flasks at a constant temperature of 370 C
in a 5% CO2 : 95% atmosphere. Cells were fed every three days and confluent cultures were sub-

28

cultured weekly. The medium content of the cells was always replaced with fresh medium 24
hours prior to sub-culturing.

In order to subculture the cells, the culture medium was aspirated and the cells were rinsed with
10 ml of sterile PBS (370 C). Cells were treated with 3 ml of trypsin-EDTA (Gibco-BRL, Cat
No. 25300-062), and the flask was placed back into the incubator. The cells were monitored until
disassociation from the bottom of the flask. The cell suspension was then transferred into a 15 ml
conical tube containing 7 ml of serum containing medium. The cell pellet was obtained upon 7
min centrifugation at 10,000 rpm after removing the supernatant. Following suspension of the
pellet in 10 ml of the medium, 1.5 ml of the cell suspension was added into a flask containing 15
ml of culture medium. When the cells were evenly distributed in the flask, the flask was placed
in the incubator.

Stable Transfection of the Cells

Transfection of MT-3 Gene into MT-3 Negative Cell Lines:

The MCF-7, T-47D, Hs578-T, MDA-MB-231 and MCF-10A cells were stably transfected with a
plasmid construct containing the MT-3 gene coding sequence, blunt-end ligated into the EcoR V
site of pcDNA 3.1/hygro (+) (Invitrogen, Carsbad, CA). The MT-3 gene was obtained from
human proximal tubule (HPT) cell RNA by RT-PCR and the linearization of the plasmid was
attained by Fsp I restriction enzyme prior to the transfections. All the cell lines were transfected
with the MT-3 plasmid construct in the sense direction or the vector without insert using the
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EffecteneTM transfection reagent (Qiagen, Valencia, CA). Prior to transfection, the hygromycin B
sensitivity curve of the cell lines was determined by adding increasing concentrations of the
antibiotic into the medium of the cells in a 12-well plate. The optimal concentration of
hygromycin B was aimed to that which gave 100% kill by the end of a week. For all cell lines,
100 µg/ml of hygromycin B produced 100% kill in a week.

The cells were seeded at a 50 % confluence in a 6-well plate (9.6 cm2/well) the day before
transfection. The transfection protocol for one well of 6-well plate is as follows. One µg of the
plasmid was diluted in 10 µl sterile water to give 0.1 µg/µl DNA. With the DNA condensation
buffer, buffer EC, the total volume was brought up to 150 µl. One to 8 DNA:Enhancer (w:v)
ratio was previously determined to be optimum for particular cell lines. After addition of 8 µl of
Enhancer, the mixture was vortexed for 2 seconds and incubated at room temperature for 5
minutes. Twenty five µl of Effectene reagent was added to the DNA-Enhancer mixture.
Following vortexing for 10 seconds, the mixture was incubated for 10 minutes at room
temperature to allow the lipid complex formation. Then, 1.5 ml media (with the serum) was
added to the tube containing the transfection complex. The complex was added on to the cells
that were previously washed twice with PBS. The plate was then gently swirled and placed into
an incubator for overnight incubation. The following morning, transfection complexes were
removed and cells were passaged at ratios of 1:10, 1:20, 1:40 and 1:80 in an appropriate selective
media to allow for clone formation. In approximately two weeks, clones expressing the
hygromycin B resistance gene started forming. As the clones reached a size visible to the naked
eye, cloning rings were utilized to isolate and transfer cells to one well of a 12-well plate for
further expansions. Finally, the clones were transferred to 6-well plates from which they were
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harvested for RNA, protein and preserved in liquid nitrogen for future studies. Throughout the
expansion process, the cell medium contained 100 µg/ml hygromycin B to keep the cells under
selective pressure. Clones expressing the MT-3 gene and vector only were chosen by RT-PCR
using insert primers that recognize the 3’ and 5’ ends of the MT-3 insertion point on pcDNA3.1
hygro (+) plasmid. The product of the PCR reaction is 395 bp in size.

Transfection of MT-1E Gene into MT-1E Negative Cell Lines:

The MCF-7 and T-47D cell lines were stably transfected with a plasmid construct containing
MT-1E gene coding sequence, blunt-end ligated into EcoR V site of pcDNA 3.1/hygro (+)
(Invitrogen, Carsbad, CA). This vector has a cytomegalovirus mediated-early promoter upstream
of the multiple cloning site and a hygromycin B resistance gene driven by an SV40 early
promoter. The MT-1E gene was obtained from human proximal tubule (HPT) cell RNA by RTPCR. The cell lines were transfected with the MT-1E plasmid construct in the sense direction or
the vector without insert using the EffecteneTM transfection reagent (Qiagen, Valencia, CA). The
plasmid DNA construct was linearized by Fsp I prior to transfection. The MCF-7 and T-47D
cell lines were transfected with the MT-1E plasmid construct in the sense direction or the vector
without insert using the EffecteneTM transfection reagent (Qiagen, Valencia, CA). Prior to
transfection, the hygromycin B sensitivity of the cell lines was determined by adding increasing
concentrations of the antibiotic into medium of the cells in a 12-well plate. The optimal
concentration of the hygromycin B was aimed to be that which gave 100% kill by the end of a
week. For all the cell lines, 100 µg/ml of hygromycine obtained 100% kill in a week.

31

The cells were seeded at a 50 % confluence in a 6-well plate (9,6 cm2/well) the day before
transfection. The transfection protocol for one well of 6-well plate is as follows. One µg of the
plasmid was diluted in 10 µl sterile water to give 0.1µg/µl DNA. With the DNA condensation
buffer, buffer EC, the total volume was brought up to 150 µl. One to 8 DNA : Enhancer (w:v)
ratio was previously determined to work the best for each cell line. After addition of 8 µl of
Enhancer, the mixture was vortexed for 2 seconds and incubated at room temperature for 5
minutes. Twenty five µl of Effectene reagent was added to the DNA-Enhancer mixture.
Following vortexing for 10 seconds, the mixture was incubated for 10 minutes at room
temperature to allow the lipid complex formation. Then, 1.5 ml media (can contain serum) was
added to the tube containing the transfection complex. The complex was added on to the cells
that were previously washed twice with PBS. The plate then was gently swirled and placed into
an incubator for an overnight incubation. The following morning, transfection complexes were
removed and the cells were passaged at ratios of 1:10, 1:20, 1:40 and 1:80 in an appropriate
selective media to allow for clone formation. In approximately two weeks, clones expressing the
hygromycin B resistance gene started forming. As the clones reached to a size visible to the
naked eye, cloning rings were utilized to isolate and transfer cells to one well of a 12-well plate
for further expansions. Finally, the clones were transferred to 6-well plates from which they were
harvested for RNA, protein and preservation in liquid nitrogen for future studies. Throughout the
expansion process, the cell medium contained 100 µg/ml hygromycin B to keep the cells under
selective pressure. Clones expressing the MT-E gene and vector only were chosen by RT-PCR
using insert primers that recognize the 3’ and 5’ ends of the MT-1E insertion point on pcDNA3.1
hygro (+) plasmid. The product of the PCR reaction is 354 bp in size.
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Isolation of mRNA from Cells

The total RNA was isolated from MCF-7, T-47D, Hs578-T, MDA-MB-232 and MCF-10A using
the TRI-Reagent® protocol (Molecular Research Center, Inc. Cincinnati, OH, USA). Following
removal of media, cells were washed with PBS and 0.5 µl of TRI-Reagent was applied to the
cells (per well of 6-well plate). Cells were incubated at room temperature for about 10 minutes to
allow complete disassociation of nucleo-protein complex. Then the content of the well was
transferred to an RNase free microfuge tube. The cell lysates were stored at -700 C.

In order to isolate RNA, samples were thawed at room temperature and 50 µl of BCP reagent
(Bicinchoninic Acid) was added to each tube. The tubes were vortexed vigorously for 20 seconds
and incubated at room temperature for 15 minutes. Then tubes were centrifuged at 40 C for 15
minutes at 14,000 rpm, and the colorless upper aqueous phase was transferred to new RNase free
microfuge tubes. In order to precipitate the RNA, 250 ml of isopropanol was added. The tubes
then were placed into a centrifuge for 15 minutes at 14,000 rpm. The supernatants were removed
and the RNA pellets were washed twice in 1 ml of 75% ethanol. After the second ethanol wash,
the pellets were dried at room temperature for 45 minutes. Finally, the fully dried RNA pellets
were eluted in 30 µl of RNase free water and stored at -700 C.

The RNA samples were quantitated by adding 3µl of stock RNA sample into 97 µl of phosphate
buffer saline in a microfuge tube. Then the samples were analyzed in a spectrophotometer and
the absorbance was read at 260 and 280 nm. The RNA concentrations were calculated by
multiplying the absorbance at 260 nm by 40 µg/ml and by the volume of the sample (100µl), and
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dividing it by the volume of the RNA sample (3µl). The working RNA solutions were prepared
at a concentration of 0.167 µg/µl and stored at -700 C for RT-PCR analysis.

Isolation of Protein from Cells

The cell media was removed and the cells were rinsed with PBS twice. After removal of PBS,
0.5 ml of 10 mM Tris-Cl (pH 8.0) supplemented by dithiothreitol (DDT) (final concentration of
1mM) was added to the cells. The cells were scraped from the bottom of the plate and transferred
to 1.5 ml microfuge tubes. Then the cells were lysed by two cycles of freezing and thawing in
liquid nitrogen and 370 C water bath. Finally, the cells were centrifuged at 14,000 rpm for 20
minutes and the supernatants were stored at -70 0 C.

RNA Isolation from Breast Tissue Specimens

Total RNA extracted from human breast tissue obtained from two cases of elective reduction
surgeries. The tissue source was anonymous, no clinical data was recorded, and the samples were
obtained following completion of diagnostic protocols. The tissue specimens were dissected free
from attached fat prior to the isolation of total RNA based on the different textures and colors of
the tissue types. Fatty tissue was identified as gelatinous and yellow while the ductal tissue was
identified as firm and tan. Immediately after dissection, 50-100 mg of breast ductal tissue
samples were transferred to RNAase free eppendorf tubes and placed in liquid nitrogen. Frozen
tissue specimens then were ground to a powder using a pedestal under liquid nitrogen. Total
RNA was isolated from the powdered tissue according to protocol supplied with the TRI
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ReagentTM (Molecular Research In., Cincinnati, OH). TRI ReagentTM (1 ml) was added to 50-100
mg powdered breast tissue and vortexed to allow homogenization. After the phase separation at
room temperature for 15 min, the samples were centrifuged at 14,000 rpm for 20 min at 40 C.
RNAs were precipitated from the aqueous phase with 1.25 ml isoprophanol. Following
centrifugation at 14, 000 rpm for 15 min at 40 C, liquid was decanted, leaving the RNA pellet.
The pellet was washed three times with 1ml of 75 % ethanol and air-dried at room temperature
for 45 min. Finally, the fully-dried RNA pellets were eluted in 30 µl of RNase free water and
stored at -700 C.

The RNA samples were quantitated by adding 3µl of stock RNA sample into 97 µl of phosphate
buffer saline in a microfuge tube. Then the samples were analyzed in a spectrophotometer and
the absorbance was read at 260 and 280 nm. The RNA concentrations were calculated by
multiplying the absorbance at 260 nm by 40 µg/ml and by the volume of the sample (100µl), and
dividing it by the volume of the RNA sample (3µl). The working RNA solutions were prepared
at a concentration of 0.167 µg/µl and stored at -700 C for RT-PCR analysis.

Protein Isolation from Breast Tissue Specimens

Total protein was extracted from human breast tissue obtained from two cases of elective
reduction surgeries. The tissue source was anonymous, no clinical data was recorded, and the
samples were obtained following completion of diagnostic protocols. Frozen tissue specimens
were ground to a powder using a pedestal under liquid nitrogen. Then, powdered tissue samples
were homogenized in 1 ml of 10 mM Tris-Cl (pH 8.0) supplemented by dithiothreitol (DDT)

35

(final concentration of 1mM). Following homogenization, samples were lysed by two cycles of
freezing and thawing in liquid nitrogen and 370 C water bath. Finally, the specimens were
centrifuged at 14,000 rpm for 20 minutes and the supernatants were stored at -70 0 C.

Protein Determination

Bio-Rad Protein Assay (Bio-Rad, Hercules, CA USA) was used to determine protein
concentrations for each of the samples. Ten µg/µl of bovine serum albumin (BSA, Fisher
Scientific, Fair Lawn, NJ, USA. Cat No. BP1605-100) was used to make standard solutions
containing 0, 0.5, 1, 1.5, 2, 2.5, 3 and 3.5 µg BSA per 10 µl. First two wells of a 96-well plate
were assigned as blanks (10 ul of water and 5 ul of 10mM Tris-Cl buffer) and standards
containing 10 µl of each standard solution and 5 µl of Tris-Cl buffer were loaded in subsequent
wells in duplicates. Rest of the empty wells were assigned for samples. Five µl of protein
samples were mixed with 10 µl of deionized water and loaded in triplicates. Before adding BioRad protein reagent into wells, the agent was filtered through a paper filter using an air vacuum
and diluted with water at a ratio of 1:5. Two hundred µl of this dilution was added to each well
of 96 well using a multichanel pipette aid. After incubation at room temperature for 5 minutes,
the plate was scanned by Dynatech MR5000 plate reader (Dynatech Inc., Guernsey Channel
Islands). Protein concentration for each sample was calculated by the regression of standard
optical densities.
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Reverse Transcription Polymerase Chain Reaction (RT-PCR)

All RT-PCR reactions were run using 0.5 µg total RNA from samples. Master mixes were
prepared using PCR Core Kits (Perkin-Elmer-Cetus, Foster City, CA, USA, Part No. N8080017) by mixing 5mM MgCl2, 1x PCR Buffer II, 1mM dATP, 1mM dCTP, 1mM dGTP, 1mM
dTTP, 2.5 mM random hexamers, 1U/µl RNase inhibitor and 2.5 U/µl MuLV reverse
transcriptase in a microfuge tube. Aliquots of 1.5 µl (0.25 µg) of total RNA samples were placed
in sterile PCR reaction tubes on ice and thoroughly mixed master mix solution was added (8.5
µl) to RNA containing reaction tubes. In addition to the samples, every RT-PCR reaction
contained two negative controls. One of the control reaction tubes included all the RT-PCR
reagents but Reverse Transcriptase, and the second control tube did not include RNA sample.
The missing amounts of Reverse transcriptase or RNA were replaced by Millie Q water. All the
reaction tubes were transferred to a PCR rack and placed in a DNA thermocycler (Perkin –Elmer
GeneAmp PCR System 9600). The reverse transcription steps were as follows: a single cycle of
250 C for 10 minutes, 420 C for 20 minutes, 990 C for 5 minutes. The reaction tubes were taken
out from the thermocycler to proceed to the PCR step. At this point it is possible to store tubes at
– 20 0 C overnight.

PCR master mixes were prepared with 2 mM MgCl2, 1x PCR Buffer II, upper and lower primers
(See appendix B), 1.25 U AmpliTaq® DNA polymerase and Millie Q water to bring the volume
of each reaction up to 40 µl. The MgCl2, PCR Buffer II and AmliTaq® were provided by PerkinElmer GeneAmp RNA PCR Core Kit. The master mix tube was vortexed and placed on ice
before combining it with sample from transcription step. The PCR reaction steps were as
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follows: DNA sample was denatured at 950 C for 2 minutes and successive cycles of temperature
change took place between annealing and extension at 680 C and denaturation at 950 C. The PCR
reactions were samples at 25, 30, and 35 cycles for the metallothionein genes. Aliquots of 15 µl
PCR reactions were taken at these specific cycles and refrigerated for electrophoresis analysis.
One and a half µl of 10x loading buffer was mixed with 15 µl of PCR product and
electrophoresed on an ethidium bromide stained 2% agrose gel.

Agarose Gel Electrophoresis

Two percent agrose gels were prepared by combining 2 grams of PE-Xppess GeneAmp® Agrose
(Perkin- Elmer, Cat No. 930-2774) with 100 ml of Gel Mix Running Mate 0.5X TBE Buffer
(Gibco-BRL, Cat No. 15546-013). The mixture was heated in microwave for approximately 3
minutes until the agrose was completely in solution. After the agarose cools to manageable
temperatures, 2.5 µl of 10mg/ml EtBr was added to 100 ml of agarose solution. After swirling
several times, the agarose solution was poured into a gel mould containing combs. The agarose
was allowed to solidify at room temperature for 1 hour. Before loading 10 µl of PCR products,
the comb was carefully removed and the agarose was transferred to an electrophoresis apparatus
filled with 0.5X TBE running buffer. The fist lane was loaded with 10 µl of Hi-Lo™ DNA
markers and the following wells with 10 µl of PCR products. The gel was run at 150 amps for
about 1.5 hours, and visualized on a UV tray. The digital images of the gel were obtained using
KODAK Professional DCS 420 digital camera interfaced with Adobe Photoshop™ software.
Finally, the intensity of the RT-PCR product bands were quantitated as integrated optical density
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(IODs) using Kontron KS 400 image analysis software (Carl Zeiss Vision, Thornwood, NY,
USA).

Dot Blots:

An immuno-blot analysis, dot blot, technique was utilized to determine the MT ½ or MT-3
protein levels. For MT-1 and -2 protein determination, standards were prepared using protein
extracted from a Metallothionein Null immortalized fibroblast cell line, MT 1/2 standard protein
(Sigma Chemical Co., St Louis, Mo, USA) and PBS. Ninety six well plates were utilized to load
the samples. Four rows out of 12 were dedicated for standards and the standard range was
determined based on MT protein levels measured by preliminary observations. For MT-1 and -2
protein, standards ranged from 0 to 10 ng MT protein (0, 1, 2, 4, 6, 8, 9, 10 ng MT). Standards
were prepared as follows; 1.5 times the desired amount of purified rabbit liver Cd/Zn
metallothionein-1 protein (as a standard) (Sigma Chemical Co., St Louis, MO, USA) were
loaded in four alternating rows, with each standard well containing 1.5 µg of protein extract from
the MT Null cell line. The standard wells were brought to a volume of 75 µl with PBS. Then the
samples were loaded into wells in triplets (1.5 µg total protein) and the volume of the wells was
brought up to 75 µl with 1 X PBS. Using a multichannel pipetman, 75 µl of 3% glutheraldehyde
was added to each well, and the contents were thoroughly mixed by pipetting up and down
several times. The plate was kept at room temperature for 30 minutes while the blot apparatus
was being prepared.
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MT-3 dot blot preparations were slightly different from MT-1 and 2 blot preparations. For MT-3
protein determination, standards were prepared using a synthetic peptide of 8 unique amino acid
conjugated to bovine serum albumin (Sigma Chemical Co., St Louis, MO), 3 µg of BSA and 1 X
PBS. Ninety six well plates were utilized to load the samples. Four rows out of 12 were
dedicated for standards and the standard range was determined based on MT-3 protein levels
measured by preliminary observations. For MT-3 protein determination, standards ranged from 0
to 0.3 ng MT protein (0, 0.01, 0.03, 0.06, 0.12, 0.18, 0.24, 0.3 ng MT-3). Standards were
prepared as follows; 1.5 times the desired amount of MT-3 cross linked peptide (as a standard)
(Sigma Chemical Co., St Louis, MO, USA) were loaded in four alternating rows, with each
standard well containing 3 µg of BSA. The standard wells were brought to a volume of 75 µl
with 1 X PBS. Then the samples were loaded into wells in triplets (3 µg total protein) and the
volume of the wells was brought up to 75 µl with 1 X PBS. Using a multichannel pipetman, 75
µl of 3% glutheraldehyde was added to each well, and the contents were thoroughly mixed by
pipetting up and down several times. The plate was kept in room temperature for 30 minutes
while the blot apparatus was being prepared.

For each blot, an 8 cm x 12 cm piece of Sequi-Blot™ PVDF membrane (Bio-Rad, Cat No.1620182) was cut and soaked in methanol for 5 minutes and submerged in 1 X PBS for 15 minutes.
The dot blot apparatus was assembled and the lower chamber was filled with 1 X PBS using 50
ml syringe. The syringe remained attached to the apparatus and the PVDF membrane was
carefully placed over the rubber adopter which contains 96 holes to allow the drainage. The top
piece of the apparatus was screwed in tightly and the wells were filled with 600 ml of 1 X PBS.
In order to obtain gravity dependent drainage, 50 ml of 1 X PBS was sucked through and then
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slowly withdrawn from apparatus. The wells were filled up with 1 X PBS again and allowed
complete drainage of 1 X PBS from the wells after the syringe was removed. Excess amount of 1
X PBS was collected in a beaker. After making sure all the PBS had soaked through the
membrane, 100 µl of each sample were transferred from the 96-well plate to the dot blot
apparatus using a multichannel pipetman. After the samples drained completely, each well was
rinsed twice with 600 µl of 1 X PBS. The apparatus was dismantled after all the 1 X PBS drained
from the top piece. Finally, the membrane was removed and soaked in 1 X PBS at 40 C
overnight.

The following day, the membrane was blocked in 10 % (w/v) milk solution made in 1 X PBS for
an hour. During blocking, the membrane was placed on a shaker to agitate it constantly. After an
hour on shaker, blocking solution was discarded and the membrane was rinsed with 1 X PBS
three times quickly. The membrane then rinsed with 1 X PBS three times for 15 minutes. Then
the membrane was incubated with primary antibody (see appendix) for an hour on a shaker.
Following 3 quick successive 1 X PBS rinses, the membrane was again rinsed three times 15
minute long with 1 X PBS. The membrane then was incubated with secondary antibody for an
hour and quick rinsed three times with 1 X PBS. After two 15 minute 1 X PBS rinses, the
membrane was rinsed with alkaline phosphatase buffer for 15 minutes. Finally, the colorimetric
detection of the alkaline phosphatase conjugated secondary antibodies was performed using an
alkaline phosphatase Vectastain ABC-AP kit (Vector Laboratories, Burlingame, CA, USA). Ten
drops of each reagent 1, 2 and 3 were added in succession to 25 ml of 100 mM Tris-HCl (pH 8.2)
and the solution was poured on the membrane. Standard detection time was usually two or three
minutes. Then, the membrane was rinsed immediately in tap water as soon as the control wells
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became visible, and left to air dry on a piece of Whatmann paper overnight. Digital image of the
membrane was generated using Epson® Expression 63 color scanner and Adobe® Photoshop®
software. The intensity of the metallothionein protein dots were quantitated as integrated optical
densities (IODs) using Kontron KS 400 image analysis software. The amount of MT protein in
each dote was determined by comparing the IODs of each sample to that of the standard curve.

Metallothionein Gene Characterization and Protein Expression by Exposure of MCF-10A
Cells to CdCl2 for 48 hours (Short Term) and 16 days (Long Term):

The MCF-10A cells were exposed to CdCl2 in order to characterize metallothionein gene and
protein expression. For 48 hours of CdCl2 exposure, enough number of T-75 flasks of MCF-10A
cells were cultured until all the flasks reached confluence. Cells were fed the day before seeding
into 6-well plates. All the 6-well plates were fed every three days with 2 ml of media until the
cells reached confluence. Twenty four hours before the exposure of CdCl2, the cells were fed
with fresh media.

On the day cells reached confluence, 7, 15 and 30 µM CdCl2 containing media were prepared
and added to the cells. The MCF-10A cells in 6-well plates were harvested at 0, 4, 8, 12, 24, 36
and 48 hour time points for RNA, protein and toxicity determination. The cells were harvested in
triplets for each time point and concentrations.

For 16 days of CdCl2 exposure, enough number of T-75 flasks of MCF-10A cells were cultured
until all the flasks reached confluence. Cells were fed the day before seeding them into 6-well
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plates. All the 6-well plates were fed with 2 ml of media every three days until the cells reached
to confluence. Twenty four hours before the exposure of CdCl2, the cells were fed with fresh
media.

On the day cells reached confluence, 3, 7, 15 and 30 µM CdCl2 containing media were prepared
and added to the cells. The MCF-10A cells in 6-well plates were harvested at 0, 1, 2, 4, 7, 10, 13
and 16 day time points for RNA, protein and toxicity determination. The cells were harvested in
triplets for each time point and concentration. Cells were fed with fresh media 24 hour before
harvests at each time point.

Colony Formation Assay:

The cell lines MCF-7, T-47D, Hs578-T and MDA-MB-231 were maintained in T75 flasks and
fed the day before setting up the colony formation assay. Confluent flasks were tripsinized using
3 ml of tripsin-EDTA (Bibco-BRL, Cat No. 25300-062), and the flasks were placed into an
incubator until the cells disassociated. Then the cells were washed and transferred from flasks to
15 ml tubes using 10 ml of 1 X PBS. The tubes were centrifuged for 7 minutes at 10, 000 rpm,
after which, the supernatant was removed and thoroughly resuspended in 10 ml of media.
Aliquots of 1 ml of the cell suspension were aliquoted out and placed into several conical tubes
containing media until dilution of 100 cell/well was achieved. The cells were counted by a
hemocytometer to make sure dilutions contained desired number of cells per ml of media. Then
the cells were seeded into 6-well plates in triplets in a manner that each well contained 100 cells.
The plates were incubated overnight at 370 C to allow cells to attach to the bottom of the plates.
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The following day, the cells were given various concentrations of CdCl2 ranging from 0 µM to
10 µM. During 3 weeks, the cells were fed every 3 days with various concentrations of CdCl2
until they formed colonies visible to the naked eye. After 3 weeks, the plates were taken out from
the incubator, fixed using 70 % EtOH for 10 minutes, and stained with crystal violet. Plates were
left at room temperature overnight to dry. Colonies containing at least 150 cells were counted.
The number of colonies formed at each concentration of CdCl2 was determined averaging triplet
wells.

Growth Curves:

To determine if MT-3 or MT-1E overexpression had any effect on the growth of MCF-7, T-47D,
Hs578-T and MDA-MB-231 cells, growth rates were determined for untransfected wild-type
cells, blank vector transfected cells and three clones of MT-3 or MT-1E transfected clones. This
was accomplished by sub-culturing the cells at a 1:10 ratio and monitoring the growth of the
cells by the automated counting of DAPI-stained nuclei until the cells reached confluence.

The cells were maintained in T75 flasks and fed every three days until they reached confluence.
Twenty four hours prior to setting up the growth experiment, cells were fed with fresh media.
The following day, cells were tripsinized and the cell suspensions were prepared in 10 ml of
media. After a series of dilutions, aliquots were taken from the cell suspensions and counted
using a hemocytometer. For all cell lines, 2 ml of cell suspensions containing 50,000 cells/ml
were seeded into 6-well plates in triplets with MT-3 or MT-1E clones, vector alone clones and
non transfected-parent cells. The plates were harvested daily until cells reached confluence.
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Depending upon the cell line, it took 8 to 11 days for cells to reach confluence. Cells harvested
daily were rinsed in 1X PBS and fixed with 70 % ethanol. Two ml of 1 X PBS was placed in
each well and cells were stained with 10 µl of DAPI dilactate (10mg/100ml in H2O). An
automated-counting of DAPI-stained nuclei was performed using Kontron Image Analysis
Software. All the experimental groups were run in triplets.

Crystal Violet Staining:

Preparation of crystal violet solution is presented in Appendix C. Following 3 weeks of colony
growth, plates were ready for crystal violet staining. Media were aspirated from the plates and
the colonies were rinsed with 1 x PBS twice before fixation with 70 % ethanol. Colonies were
fixed with 70 % ethanol for about 7 minutes and rinsed once again with 1 x PBS solution. Each
well was treated with 0.5 ml of crystal violet solution for a minute. Then the wells were rinsed
thoroughly with 2 ml of 1 x PBS twice. After 30 minutes of air-drying at room temperature,
colonies visible to naked eye were counted independently at least three times per well.

Laser Captured Microdissection (LCM):
The Laser Captured Microdissection System, The PixCellTM LCM (Arcturus Engineering,
Mountain View, CA) was used for microdissection protocol. Five um thick sections were cut
from formalin-fixed, paraffin embedded tissue blocks of normal human breast obtained from the
pathology archives and mounted on plain glass slieds. The slides were stained with hematoxylin
and eosin. Total RNA was extracted from samples using the micro RNA isolation kit
(Stratagene, La Jolla, CA, Catalog No: 200344).
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STABLE TRANSFECTION AND OVEREXPRESSION OF METALLOTHIONEIN
ISOFORM 3 INHIBITS THE GROWTH OF MCF-7 AND Hs578T CELLS
BUT NOT THAT OF T-47D OR MDA-MB-231 CELLS.
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INTRODUCTION

Third isoform of the metallothionein gene family (MT-3) is overexpressed in a subset of human
breast cancers and that overexpression correlates with poor disease prognosis [1]. Using a
similar retrospective analysis of paraffin embedded archival samples, it has also been shown that
MT-3 is highly expressed in all human bladder cancers examined to date [2] and has a variable
expression in prostate cancers compared to control tissue [3]. MT-3 is a member of the MT gene
family which, in the human, is composed of at least 10 active genes and 7 pseudogenes [4,5,6,7].
All family members share the property of being low molecular weight (6 kDa), intracellular
proteins that have a very high conserved number of cysteine residues that function to allow the
efficient binding of transition metals [8]. There are several features that distinguish MT-3 from
the other MT family members. The MT-1 and MT-2 isoforms exhibit a ubiquitous pattern of
tissue expression and are highly inducible by any number of stimuli, where as, MT-3 exhibits
neither of these characteristics [9,10,11]. The major structural difference between MT-3 and all
other MT isoforms is that the MT-3 isoform possesses 7 additional amino acids that are not
present in any other member of the MT gene family, a 6 amino acid C-terminal sequence and a
Thr in the N-terminal region [6,9,12]. Of interest in the current study is that the MT-3 protein
has been shown to inhibit the survival and neurite outgrowth of cultured rat cortical neurons
when added exogenously to such cultures [9,13] and to have a growth inhibitory activity when
expression is indirectly elevated in cultures of rat C-6 glial cells [14]. The growth inhibitory
activity in the neural cells is unique to MT-3 and is not duplicated by the other members of the
MT gene family [12,15]. This non-duplication of function occurs despite a 63-69% identity in
amino acid sequence among MT-3 and the other 9 active human MT isoforms [12]. A recent
study has shown that stable transfection of PC-3 prostate cancer cells with MT-3 results in
growth inhibition, extending the growth inhibitory action of MT-3 beyond the neural system
[11]. Transfection of the PC-3 cells with the MT-1E isoform had no effect on cell growth,
confirming that the growth inhibitory activity was also MT-3 specific in prostate cancer cells. In
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contrast, the resistance of the PC-3 cells to cadmium was enhanced by both the MT-3 and MT1E isoforms.

The goal of the present study was to determine if MT-3 overexpression would

influence the growth of human breast cancer cell lines. To determine this, the coding sequence of
the MT-3 gene was stably transfected into 2 estrogen receptor positive (MCF-7 and T-47D) and
2 estrogen receptor negative cell lines (Hs578T and MDA-MB-231) having no basal expression
of MT-3.

RESULTS

Stable Transfection and Expression of MT-3 in MCF-7, T-47D, Hs578T and MDA-MB-231
Cells:

It was determined using RT-PCR at a total RNA input of 1 µg and 40 reaction cycles that there
was no basal expression of MT-3 mRNA in the MCF-7, T-47D, Hs578T or MDA-MB-231 cell
lines (Fig 4 A,C,E,G). Immuno-blot analysis of the corresponding protein sample from these 4
cell lines also demonstrated no detectable MT-3 protein (Table 1). The coding sequence of the
MT-3 gene was obtained from human proximal tubule cell RNA by RT-PCR, blunt end ligated
into the EcoR V site of pcDNA3.1/Hygro(+), and linearized by Fsp I prior to transfection of the
respective cell lines. All four cell lines were transfected with the MT-3 plasmid construct in the
sense direction or with the blank vector by application of the Effectene protocol. Following
selection in hygromycin B-containing growth medium, 5 clones from each cell line were selected
for further characterization. Each of the 5 clones from each cell line overexpressed MT-3 mRNA
when compared to wild type cells or cells containing the blank pcDNA3.1 vector (Fig 4
A,C,E,G). The MT-3 mRNA was first detected from each of the 5 overexpressing clones of each
cell line between 20 and 22 cycles of PCR with cDNA derived from 500 ng total RNA inputs.
This level of expression was similar to that of the glyceraldehyde 3-phosphate dehydrogenase
gene. It was also demonstrated that the transfection protocol had no effect on the expression on
48

the glyceraldehyde 3-phosphate dehydrogenase housekeeping gene (Fig 4 B,D,F,H). The MT-3
protein was not detected in the 4 cell lines transfected with the blank vector, but was detectable
in the clones of each cell line of the MT-3 transfectants (Table 1).
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Figure 4. MT-3 and glyceraldehyde 3-phosphate dehydrogenase (G3PDH) gene expression
in transfected MCF-7, T-47D, Hs578T and MDA MB 231cells.

RT-PCR was used to

determine the expression of MT-3 and G3PDH mRNA. The reactions were sampled at 30, 35 and
40 cycles of PCR for the MT-3 transfected clones and the control cells, and the reaction products
were visualized on ethidium bromide (EtBr) stained 2% agrose gels. Shown in A, C, E, G are the
MT-3 RT-PCR products at 30 cycles of PCR for the five independent MT-3 clones, 40 cycles of
PCR for the two clones containing blank vector and the two samples of nontransfected MCF-7,
T-47D, Hs578T and MDA MB 231 cells. Shown in B, D, F, H are the G3PDH products at 30
cycles for five independent MT-3 clones, two clones with blank vector and two samples of
nontransfected MCF-7, T-47D, Hs578T and MDA MB 231 cells.
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Stable Transfection and Expression of MT-1E in MCF-7 and T-47D Cells:

It has been shown previously that the Hs578T and MDA-MB-231 cell lines express mRNA for
the MT-1E isoform, while the MCF-7 and T-47D cell lines have no expression of the MT-1E
gene [16]. For this reason, the MT-1E gene was transfected only into the MCF-7 and T-47D cell
lines. It was confirmed using RT-PCR that both MCF-7 and T-47D cell lines did not express
MT-1E mRNA following 40 cycles of PCR at an input of 1µg total RNA (Fig 5 A). However,
immuno-blot analysis of corresponding triplicate protein samples from the wild-type MCF-7 and
T-47D cell lines demonstrated that these cell lines did have MT-1 and MT-2 protein (Table 1).
This finding was expected since the E9 antibody used for MT-1 and MT-2 protein
determinations cannot distinguish between the MT-1 and MT-2 isoforms, and the MT-2A and
MT-1X genes have been shown previously to be expressed in both the MCF-7 and T-47D cell
lines [16]. The amount of MT-1/2 protein found was consistent with the previous findings in
these cell lines [16]. The coding sequence of the MT-1E gene was also obtained from human
proximal tubule cell RNA by RT-PCR, blunt end ligated into the EcoR V site of
pcDNA3.1/Hygro(+), and the resulting construct linearized by Fsp I prior to transfection of the
MCF-7 and T-47D cells. An identical protocol was used to transfect the cells with the MT-1E
plasmid. Similarly, it was demonstrated that each of 5 independent clones from each cell line
overexpressed MT-1E mRNA when compared to wild-type cells or cells containing the blank
pcDNA3.1 vector (Fig 5 A,C).

The MT-1E mRNA was first detected from each of the

respective 5 overexpressing clones at 22 cycles of PCR and 500 ng total RNA inputs. This level
of expression was similar to that of the glyceraldehyde 3-phosphate dehydrogenase gene and
expression of this housekeeping gene was also similar among all the respective clones (Fig 5
B,D). The expression of the MT-1/2 protein was significantly elevated in both the MCF-7 and
T-47D cells transfected with the MT-1E gene compared to the wild type and blank vector
controls (Table 1).
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Figure 5. MT-1E and G3PDH gene expression in MCF-7 and T-47D cells stably transfected
with MT-1E cDNA. RT-PCR was used to confirm expression of MT-1E and G3PDH mRNA.
The reactions were sampled at 30, 35 and 40 cycles of PCR for the MT-1E transfected clones
and the control cells, and the reaction products were visualized on ethidium bromide (EtBr)
stained 2% agrose gels. Shown in (A, C) are the MT-1E RT-PCR products at 30 cycles PCR for
five independent MT-1E clones, 40 cycles of PCR for the two clones with blank vector and two
samples of nontransfected MCF-7 and T-47D cells. Shown in (B, D) are the G3PDH products at
30 cycles for five independent MT-1E clones, two clones with blank vector and two samples of
nontransfected MCF-7 and T-47D cells.
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Effect of Stable Transfection of MT-3 and MT-1E on the Expression on other Isoforms of
the MT Gene Family:

Experiments were also performed to determine if the overexpression of either the MT-3 or MT1E genes had any influence on the basal levels of expression of the other 9 active MT genes in
the 4 cell lines. In the case of MT-3, this was determined by isolating total RNA from one MT-3
transfected clone and one blank vector control from each of the 4 cell lines and determining the
basal expression of the MT-1A, MT-1B, MT-1E, MT-1F, MT-1G, MT-1H, MT-1X, MT-2A and
MT-4 genes by RT-PCR. It was demonstrated using 40 cycles of PCR and a total RNA input of
1 µg that there was no expression of the MT-1A, MT-1B, MT-1F, MT-1G, MT-1H, and MT-4
genes in any of the MT-3 transfectants or vector controls of all 4 cell lines (data not shown).
This finding that these genes were not expressed was in agreement with the expression patterns
noted previously for these MT genes in the 4 parental cell lines prior to transfection [16]. In
agreement with the previous study, it was also found that the MCF-7 and T-47D cell lines had no
expression of MT-1E, where as, the Hs578T and MDA-MB-231 cell lines did express the MT1E gene (data not shown). For the MCF-7 and T-47D cell lines, it was demonstrated that the
levels of expression of the MT-2A and MT-1X genes were similar among the MT-3 transfectants
and the blank vector controls (Fig 6). Likewise, for the Hs578T and MDA-MB-231 the levels of
expression of the MT-2A, MT-1X and MT-1E genes were similar between the MT-3 transfectant
and vector controls (Fig 6). In all cases, the level of the MT-1/2 protein was also similar among
the MT-3 transfectants and the blank vector controls (data not shown). In the case of MT-1E,
total RNA was isolated from a MT-1E transfected clone and a blank vector control from the
MCF-7 and T-47D cell lines and the expression of the MT-1A, MT-1B, MT-1F, MT-1G, MT1H, MT-1X, MT-2A, MT-3 and MT-4 genes determined by RT-PCR. It was demonstrated at 40
cycles of PCR and total RNA inputs of 1µg that there was no expression of the MT-1A, MT-1B,
MT-1F, MT-1G, MT-1H, MT-3 and MT-4 genes in either the MT-1E transfectants or blank
vector controls (data not shown). The levels of expression of the MT-2A and MT-1X genes
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were similar between the MT-1E transfectants and vector controls for each cell line (Fig 6). The
MT-3 protein was not detected in either the MT-1E transfectants or the blank vector controls
(data not shown).

Figure 6. The effect of stable transfection of MT-3 and MT-1E on the expression of other
isoforms of the MT gene family. Expression of MT-2A, 1E and 1X was assessed by using RTPCR with isoform specific primers on total RNA from MT-3 or MT-1E transfected clones and
clones with blank vector. The reactions were sampled at 25, 30 and 35 cycles, and the products
were visualized on 2% ethidium bromide stained gels.
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Effect of Stable Transfection of MT-3 and MT-1E on MCF-7, T-47D, Hs578T and MDAMB-231 Cell Growth:

To determine if MT-3 overexpression had an effect on the growth of the 4 transfected cell lines,
growth rates were determined for untransfected wild-type cells, a blank vector transfectant, and
three clones of MT-3 transfectants for each cell line. This was accomplished by subculturing the
cells at a 1:10 ratio and monitoring the growth of the cells by the automated counting of DAPIstained nuclei until the cells reached saturation density. The results demonstrated that MCF-7
and Hs578T cells stably transfected to overexpress the MT-3 gene had a markedly reduced
growth rate compared to both untransfected cells or cells containing the blank vector control (Fig
7 A,B).

This marked reduction in growth was confirmed for three independent MT-3

overexpressing clones of the MCF-7 and two independent clones of Hs578T cell lines.

The

mean doubling time of the three independent clones of MCF-7 cells overexpressing MT-3 was
61.0 ± 2.9 hrs compared to a doubling time of 38.5 ± 2.9 hr in control MCF-7 cells and blank
vector transfectants (significantly different at p < 0.001). The mean doubling time of the two
independent clones of Hs578T cells overexpressing MT-3 was 97.3 ± 1.5 hrs compared to a
doubling time of 71.6 ± 1.8 hrs in control Hs578T cells and blank vector transfectants
(significantly different at p < 0.001).
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Figure 7 A, B. The effect of MT-3 on MCF-7, Hs578T cell growth. The cells were seeded at
1:10 ratio and the cell numbers were determined at indicated time points by automated counting
of DAPI-stained nuclei. Shown in panel A, B, is effect of MT-3 overexpression on MCF-7 and
Hs578T cell growth.
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In contrast, it was shown that the growth of the T-47D or MDA-MB-231 cells was unaffected by
the stable transfection and expression of the MT-3 gene (Fig 7 C, D). The mean doubling time
of the three independent clones of T-47D cells overexpressing MT-3 was 47.7 ± 1.4 hrs
compared to a doubling time of 43.4 ± 0.3 hrs in control T-47D cells and blank vector
transfectants (p > 0.05). The mean doubling time of the three independent clones of MDA-MB231 cells overexpressing MT-3 was 28.7 ± 1.3 hrs compared to a doubling time of 26.7 ± 0.4 hrs
in control cells and blank vector transfectants (p > 0.05).
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Figure 7 C, D. The effect of MT-3 overexpression on T-47D, and MDA MB 231 cell
growth. The cells were seeded at 1:10 ratio and the cell numbers were determined at indicated
time points by automated counting of DAPI-stained nuclei. Shown in panel C and D is effect of
MT-3 overexpression on T-47D and MBA-MB-431 cell growth.
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An identical protocol was utilized to determine if MT-1E overexpression had an effect on the
growth of either the MCF-7 or T-47D cell lines.

The results demonstrated that stable

transfection of the cells with the MT-1E gene had no significant effect on the growth rate of the
cells when compared to either control cells or blank vector controls (Fig 7 E,F). The mean
doubling time of the three independent clones of MCF-7 cells overexpressing MT-1E was 34.7 ±
1.7 hrs compared to a doubling time of 36.5 ± 0.1 hrs in control cells and blank vector
transfectants (p > 0.05). The mean doubling time of the three independent clones of T-47D cells
overexpressing MT-1E was 31.3 ± 0.5 hrs compared to a doubling time of 31.6 ± 0.4 hrs in
control cells and blank vector transfectants (p > 0.01).
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Figure 7 E,F. The effect of MT-1E overexpression on MCF-7, T-47D cell growth. The cells
were seeded at 1:10 ratio and the cell numbers were determined at indicated time points by
automated counting of DAPI-stained nuclei. Shown in panel E and F is the effect of MT-1E
overexpression on MCF-7 and T-47D cell growth.
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Effect of Stable Transfection of MT-3 and MT-1E on Resistance of MCF-7, T-47D, Hs578T
and MDA-MB-231 Cells to Cadmium:

Identical clones to those used above in the growth studies were used to determine if the
overexpression of MT-3 or MT-1E would increase the resistance of the cells to cadmium. For
MT-3, LD50 values were determined for each of the MT-3 expressing and non-expressing clones
when the cells were exposed to cadmium. The results of this analysis demonstrated that the
overexpression of MT-3 increased the resistance of only the MCF-7 cell line to the toxic effects
of cadmium (Fig. 8). The data are presented as the calculated LD50 ± the Wald confidence
interval for the MT-3 non-expressing and expressing clones, respectively. Identical studies for
the MCF-7 (Fig. 8) and T-47D cells (data not shown) overexpressing the MT-1E gene
demonstrated that overexpression only increased the resistance of the MCF-7 cells to the toxic
effects of cadmium.

Figure 8. The effect of MT-3 and MT-1E overexpression on Cd+2 resistance. LD50 values
were measured by colony formation assay for all four breast cancer cell lines for MT-3 clones (■
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), MT-1E clone (□), vector alone (▲) and nontransfected wild-type (●) cells. In all cases, the
error bars represent the Wald confidence interval at the 95% confidence level, calculated for
each side of the LD50 determination.

DISCUSSION

MT-3 was originally proposed as a brain-specific metallothionein with limited expression
outside the neural system [6]. A limited expression pattern of MT-3 in normal human tissues
does appear to be the norm for this protein, with the only major exception noted to date being
that of the human kidney, where moderate to high levels of expression were found in most of the
various renal epithelial cell types [10]. An interest in how MT-3 expression might affect the
cancer cell was motivated by the observation that, while MT-3 was not expressed in normal
bladder urothelium or breast epithelium, it was overexpressed in all bladder cancers and in
selected breast cancers [1,2]. In breast cancer, expression appeared to correlate with ductal in
situ carcinomas having a poor outcome [2]. In prostate cancer, MT-3 was shown to have
variable expression ranging from none to occasional instances of moderate levels in normal
prostate epithelium, and to have high levels of overexpression in some cancers and PIN lesions
and to be absent in others [3]. The finding that MT-3 was overexpressed in paraffin-embedded
diagnostic specimens from patients with bladder, prostate and breast cancer, motivated an
examination of what effect MT-3 overexpression would have in cell lines derived from these
cancers.

This was first approached in the PC-3 prostate cancer cell line when it was

demonstrated that of the LNCaP, Du-145 and PC-3 cell lines, only the PC-3 cells expressed no
detectable MT-3 mRNA and protein, making them a suitable recipient for stable transfection of
an MT-3 overexpression vector [3]. The results of this study demonstrated that PC-3 prostate
cancer cells that overexpress MT-3 have a reduced growth rate and increased chemotherapeutic
drug resistance compared to cells containing a blank vector [11]. An identical transfection
protocol for introduction of MT-1E gene was employed to show that the growth reduction was
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specific to the MT-3 isoform while chemotherapeutic drug resistance was a general feature of
cells transfected with either MT-1E or MT-3. These results served as the first demonstration that
the growth inhibitory activity of MT-3 noted in the neural system could extend to cell types of
epithelial origin. The initial goals of the present study were to determine if MT-3 expression was
growth inhibitory for breast cancer cells and if such inhibition might be a general feature of
breast cancer cell lines.

The present study demonstrated that MT-3 expression can inhibit the growth of breast cancer cell
lines as evidenced by the marked growth inhibition stable transfection and overexpression of
MT-3 elicited in the MCF-7 and Hs578T cell lines. However, it was also demonstrated that
growth reduction was not a general property of MT-3 expression in all breast cancer cell lines
since identical stable transfection and overexpression of MT-3 had no effect on the growth of the
T-47D and MDA-MB-231 cell lines. That these findings were specific for MT-3 and not a
general feature of MT overexpression was strongly indicated by the finding that the
overexpression of the MT-1E isoform gene had no effect on the growth of both cell lines. The
MT-3 gene has not been widely studied outside the neural system and there exists no established
mechanism to explain why MT-3 overexpression is growth inhibitory in the neural system or in
certain cancer cell lines. An examination of the genetic backgrounds of the 4 cell lines is not
very helpful in assigning mechanism since the 4 cell lines are very diverse and contain a variety
of both common and specific genetic deletions and mutations that accumulate in cell lines
derived from advanced cancers that have been cultured for many years. One interesting feature
was that the growth inhibition mediated by MT-3 did not correlate with the estrogen receptor
status of the cells, with 1 ER positive (MCF-7) and 1 ER negative (Hs578T) cell line
demonstrating growth inhibition.

This finding that MT-3 mediated growth inhibition is

independent of ER status agrees with earlier findings that expression of immunoreactive MT-3 in
archival specimens for breast cancer patients was also independent of this marker [1]. The ER
status of a breast cancer was originally used to predict response to endocrine ablative therapy for
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patients with advanced breast cancer, but ER is now more widely used to select patients with
early breast cancer likely to respond to the antiestrogen, tamoxifen [18]. In a meta-analysis of
over 37,000 women, ER-positive patients were 7 times less likely to develop recurrent disease
than ER-negative patients following at least 5 years of adjuvant tamoxifen treatment [19, 20].
The finding that both MT-3 expression and its effect on cell growth are independent variables
from ER status can potentially provide an additional prognostic marker to further stratify the ER
positive sub-group of breast cancers.

The effects of MT-3 on both cell growth and its role as a potential marker for breast cancer
prognosis appear to be unique properties that are distinct from the MT-1 and MT-2 members of
this gene family. The effect on cell growth is confined to the MT-3 isoform as evidenced by the
fact that MT-1E has no effect in both prostate or breast cancer cell lines. Evidence that MT-3
might have a role in predicting tumor prognosis also appears specific for the MT-3 isoform. An
antibody (E9) that recognizes both the MT-1 and MT-2 isoform proteins has been employed in
many studies to shown that co-overexpression of these two isoforms correlates to breast cancers
having an aggressive course [21-28]. However, in contrast to MT-3, which appears independent
of ER status, expression of MT-1 and MT-2 does not increase the prognostic power provided by
ER status alone. In addition to the limited tissue distribution [6], the limited number of inducing
agents [15], and growth inhibitory activity [9], there is also other evidence that MT-3 has distinct
functional properties in the brain compared to the MT-1 and MT-2 isoforms.

Despite an

approximate 70% sequence identity with MT-1/MT-2, there is recent evidence that the β-domain
of MT-3 may have different functional properties than the corresponding β-domain of the MT-1
and MT-2 isoforms [29]. Studies of CdMT-3 using
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Cd-NMR have shown that the β -cluster

region of MT-3, in contrast to MT-1/MT-2, is conformationally dynamic [30,31]. A similar
conclusion also drawn when the N-terminal region of MT-3 was not resolved by high resolution
NMR of CdMT-3 while the C-terminal part of MT-3 was shown to fold into the four metal
cluster similar to the α domain of MT-1 and MT-2 [32]. These results, together with the recent
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analysis of CdMT-3 using ESI-TOF-MS (Ettan Electrospray time-of-flight mass spectrometry),
suggest that the β-domain of MT-3 is adapted for noncooperative binding of variable
concentrations of Zn+2 or Cd+2 ions and exposes high metal exchange potential. This suggests
that one of the specific functions of MT-3 in the brain could be buffering of highly fluctuating
concentrations of zinc and transfer of zinc into zinc-requiring vesicles. These finding suggest
that breast cancer cells that overexpress MT-3 could have alterations in Zn-requiring proteins
such as p53, which requires Zn+2 to maintain an active protein confirmation.
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POST-TRANSCRIPTIONAL RESTRICTION OF METALLOTHIONEIN ISOFORM-3
(MT-3) EXPRESSION IN CULTURES DERIVED FROM HUMAN BREAST
EPITHELIAL CELLS
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INTRODUCTION

The third isoform of metallothionein (MT-3) is encoded by a single-gene member of the MT gene
family which, in the human, is composed of at least 10 active and 7 pseudogenes [1,2,3,4]. All
family members share the property of being low molecular weight (6 kDa), intracellular proteins that
have a very high number of conserved cysteine residues that function to allow the efficient binding
of transition metals [5]. The MT-1 and MT-2 members of this gene family have been extensively
studied and are believed to serve an important role in the homeostasis of essential metals such as
Zn+2 or Cu+2 during growth and development as well as in the detoxification of heavy metals such as
Cd+2 and Hg+2; rendering the MTs important mediators and attenuators of heavy metal-induced
toxicity, particularly hepato- and nephrotoxicity [5,6,7,8,9,10]. The MT-1 and MT-2 isoforms
exhibit a ubiquitous pattern of tissue expression and are highly inducible by any number of stimuli
[5,6,9,10]. The MT-3 isoform, on the other hand, has received much less attention. MT-3 has a
limited tissue distribution, being initially identified as a brain-specific MT, and is not induced by
many of the stimuli known to be inducers of MT-1 and MT-2 isoforms [1,11,12]. Although
possessing extensive homology with the MT-1 and MT-2 isoforms, there is a small, but significant
structural difference between MT-3 and all other MT isoforms. The MT-3 isoform possesses 7
additional amino acids; a 6 amino acid C-terminal sequence and a Thr in the N-terminal region
[1,11,13]. The MT-3 protein has been shown to inhibit the survival and neurite outgrowth of
cultured rat cortical neurons when added exogenously to such cultures [11,14] and to have a growthinhibitory activity when expression is indirectly elevated in cultures of rat C-6 glial cells [13]. The
growth inhibitory activity in the neural cells is unique to MT-3 and is not duplicated by the other
members of the MT gene family [12,13]. This non-duplication of function occurs despite a 63-69%

73

identity in amino acid sequence among MT-3 and the other 9 active human MT isoforms [12].

In addition to expression in the neural system, it has been demonstrated that MT-3 is overexpressed
in a subset of human breast cancers and that overexpression correlates with poor disease prognosis
[15]. Using a similar retrospective analysis of paraffin embedded archival samples, it has also been
shown that MT-3 is highly expressed in all human bladder cancers examined to date [16] and to have
a variable expression in prostate cancers compared to control tissue [17]. It was also shown in the
above studies that MT-3 mRNA and protein was not expressed in normal breast and bladder
epithelium and only weakly expressed in normal prostate epithelial cells. Recent studies have also
shown that the growth inhibitory activity of MT-3 extends beyond the neural system. The stable
transfection of PC-3 prostate cancer cells with MT-3 resulted in markedly reduced cell growth, while
transfection with the MT-1E isoform had no effect on cell growth [18]. In breast cancer cell lines,
the stable transfection and overexpression of MT-3 was shown to inhibit the growth of the MCF-7
and Hs578T cells, but to have no effect on the growth of the T-47D and MDA-MB-231 cell lines
[19]. The overexpression of MT-1E in the MCF-7 and T-47D cells had no effect on cell growth.
The goal of the present study was to determine the effect that overexpression of MT-3 would have
on the immortal, but non-tumorigenic, MCF-10A human breast epithelial cell line.
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RESULTS

Stable Transfection and Expression of MT-3 mRNA in MCF-10A Cells: It was determined
using RT-PCR at a total RNA input of 1 µg and 40 reaction cycles that there was no basal expression
of MT-3 mRNA in the MCF-10A cell line (Fig 9 A). The coding sequence of the MT-3 gene was
obtained from human proximal tubule cell RNA by RT-PCR, blunt end ligated into the EcoR V site
of pcDNA3.1/Hygro(+), and linearized by Fsp I prior to transfection of the respective cell lines. The
MCF-10A cell line was transfected with the MT-3 plasmid construct in the sense direction or with
the blank vector using the Effectene protocol. Following selection in hygromycin B-containing
growth medium, 5 clones of MCF-10A cells were selected for further characterization. It was
demonstrated that each of the 5 clones overexpressed MT-3 mRNA when compared to wild type
cells or cells containing the blank pcDNA3.1 vector (Fig 9 A). The MT-3 mRNA was first detected
from each of the 5 overexpressing clones of each cell line between 20 and 22 cycles of PCR and 500
ng total RNA inputs. This level of expression was similar to that of the glyceraldehyde 3-phosphate
dehydrogenase gene. It was also demonstrated that the transfection protocol had no effect on the
expression on the glyceraldehyde 3-phosphate dehydrogenase housekeeping gene (Fig 9 B).
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Figure 9: MT-3 and glyceraldehydes 3-phosphate dehydrogenase (G3PDH) gene expression in
transfected MCF-10A cells. RT-PCR was used to determine the expression of MT-3 and G3PDH
mRNA. The reactions were sampled at 25, 30 and 35 cycles of PCR for the MT-3 transfected clones
and the control cells, and the reaction products were visualized ethidium bromide- stained 2% gels.
(A) is the MT-3 RT-PCR products at 30 cycles of PCR for the five independent MT-3 clones using
500 ng total RNA, and 40 cycles of PCR for the two clones containing blank vector and the two
samples of non-transfected MCF-10A cells using 1 µg of total RNA. (B) is the G3PDH products at
30 cycles for five independent MT-3 clones, two clones with blank vector and two samples of nontransfected MCF-10A cells.

The relative level of MT-3 mRNA expression in the MT-3 transfected MCF-10A cells was similar to
that obtained in previous studies conducted with identical methods, in which the MT-3 sequence was
transfected into the MCF-7, T-47D, Hs578T or MDA-MB-231 breast cancer cell lines [19] and the
PC-3 prostate cancer cell line [18] that did not express MT-3 mRNA or protein (Fig 10 A).
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Failure of MCF-10A Cells Stably Transfected with MT-3 to Express MT-3 Protein:

It was

also determined that there was no basal expression of MT-3 protein in the MCF-10A cell line or in
the blank vector control, with the limit of detection in cell lysates being between 0.1 - 0.5 ng MT3/µg total cell protein (Fig 10 B). An analysis of MT-3 protein expression in the above 5 clones of
MCF-10A cells transfected with the MT-3 sequence also showed very low levels of MT-3 protein,
with all 5 clones producing MT-3 near the detection limit of the assay (Fig 10 B). That this was not
an artifact of the assay system or the cloning procedure was suggested by the finding that the
identical MT-3 sequence transfected into MCF-7, T-47D, Hs578T or MDA-MB-231 breast cancer
cell lines [19] and the PC-3 prostate cancer cell line [18] by using identical methodology yielded
elevated levels of MT-3 protein expression (Fig 10 B).
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Figure 10: The MT-3 mRNA and protein levels in MCF-10A cells. (A) is the relative levels of
MT-3 mRNA expression demonstrated by RT-PCR (B) is the levels of MT-3 protein expressionas
determined by immuno-blot analysis in five independent clones of MT-3 transfected MCF-10A cells,
non-transfected MCF-10A cells and a vector only clone. The MT-3 protein levels were also
determined in MT-3 transfected MCF-7, T-47D, MDA-MB-231, Hs578T breast cancer cell lines and
a PC-3 prostate cancer cell line. Non-transfected MCF-10A cells and vector only transfected MCF78

10A cells showed non-detectable levels of MT-3 protein. Error bars represent the standard errors.
Effect of Cd+2 on MT-3 Protein Expression in MCF-10A Cells: Since Cd+2 is bound by all
members of the MT protein family with high affinity and is an inducer of MT-1 and MT-2 gene
expression in most mammalian cell systems, studies were designed to determine what effect Cd+2
exposure would have on the accumulation of MT-3 protein in the MT-3 transfected MCF-10A cells.
The expression of MT-3 and the MT-1/2 proteins was determined on confluent MT-3 transfected
MCF-10A cells and blank vector controls when exposed to lethal (15 and 30 µM) and sub-lethal (3
and 7 µM) amounts of Cd+2 for a 16 day period (Fig 11). There was no difference in toxicity to Cd+2
among the MCF-10A parental cell line, the MCF-10A cells transfected with the blank vector control,
or the MCF-10A cells stably transfected with the MT-3 sequence (Fig 11). Similarly, there was no
difference in Cd+2 toxicity among the five MT-3 transfected MCF-10A clones (data not shown).

Figure 11: Viability of MT-3 transfected MCF-10A cells exposed to CdCl2. MT-3 transfected
MCF-10A cells were exposed to 0 µM (), 3µM ( ), 7 µM (S), 15 µM (|) and 30 µM () of
CdCl2 for 16 day of extended time course. Cell viability was determined by automated counting of
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DAPI-stained nuclei and all determinations were in triplicate. Values shown are the percentage of
the mean cell numbers at each time point divided by the mean cell numbers of the control cells for
each triplicate determination.

Exposure of the MT-3 transfected MCF-10A cells to 3 µM Cd+2 resulted in no significant increase
in the level of the MT-3 protein over that of MCF-10A cells containing the blank vector (Fig 12 A).
In contrast, this identical exposure resulted in a significant increase in the level of the MT-1/2
protein in the MT-3 transfectants and the blank vector controls (Fig 12 A). The finding that Cd+2
exposure resulted in no increase in MT-3 protein expression in the MT-3 transfected cells and
controls was confirmed at increasing concentrations of Cd+2, including those eliciting rapid cell
death (Fig 12 B, C, D). In all instances, the MT-1/2 protein level was shown to be significantly
increased by Cd+2 exposure of the cells under identical experimental conditions (Fig 12 B, C, D).
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Figure 12: MT-3 and MT 1/2 protein levels. MT-3 and MT1/2 protein levels were determined by
immuno-blot analysis in MT-3 transfected and vector only transfected MCF-10A cells after exposure
to (A) 3 µM, (B) 7 µM, (C) 15 µM and (D) 30 µM of CdCl2. MT- 1/2 protein was only determined on
days 0,1,2,10 and 16 for the blank vector control.

To check for an effect of cell proliferation on MT-3 protein accumulation, the MT-3 transfected
MCF-10A cells were also exposed continuously to 2, 4, and 6 µM of CdCl2 for 5 passages at a 1:10
subculture ratio. An analysis of MT-3 protein expression at the end of 5 passages demonstrated that
the MT-3 transfected MCF-10A cells had accumulated no MT-3 protein, with levels near the limit of
assay detection (Fig 13).

Figure 13: Analysis of MT-3 protein accumulation in MCF-10A cellsafter 5 passages. MT-3
protein levels were determined in MT-3 transfected MCF-10A cells after maintaining them for 5
passages.
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DISCUSSION

It has been demonstrated that MT-3 is overexpressed in a subset of human breast cancers and that
overexpression is associated with poor disease prognosis [15]. As part of this study, an analysis of
MT-3 mRNA expression in total RNA isolated from breast tissues obtained following elective
surgical reductions demonstrated that no MT-3 mRNA was expressed in the normal human breast.
This would indicate that at some point along the transformation pathway, the breast epithelial cell
gains the ability to express MT-3 mRNA and protein in selected cases of human breast cancer. The
finding that MT-3 was overexpressed in some ductal carcinoma in situ (DCIS) lesions provides
evidence that such overexpression might be early in the pathway leading to progression. To begin to
understand the consequences of MT-3 overexpression on the breast epithelial cell in situ, the present
study was designed to determine the effect that MT-3 expression would have on a cell culture model
of the breast epithelial cell. The cell culture model chosen for use was the immortal MCF-10A
human breast epithelial cell line that retains contact inhibition of growth and does not form colonies
in soft agar or tumors in nude mice. The initial studies using this cell line demonstrated that the
MCF-10A cells had no expression of MT-3 mRNA, a finding in agreement with that found for MT-3
mRNA expression in the in situ human breast. The finding that MCF-10A cells had no basal
expression of MT-3 mRNA allowed an experimental strategy to be employed that involved the
stable transfection and overexpression of the MT-3 gene into this cell line using widely employed
and established methodology.

The stable transfection of MT-3 into the MCF-10A cell line did not result in the expected
overexpression of MT-3 mRNA and protein. Rather, it was demonstrated that stable transfection
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resulted only in the expected overexpression of MT-3 mRNA, but that there was no corresponding
expression of the MT-3 protein. There is strong evidence that the lack of MT-3 protein expression
was a legitimate finding and not due to a failure of the transfection technology. The most important
evidence is that the identical vector has been used successfully for the stable transfection of the MT3 sequence into the MCF-7, T-47D, Hs578T and MDA-MB-231 breast cancer cell lines [19], and the
PC-3 prostate cancer cell line [18]. As detailed in the results, all 5 of these cell lines produced
comparable amounts of MT-3 mRNA and increased amounts of the MT-3 protein. The stable
transfection of MT-3 into these cell lines resulted in marked growth inhibition for the MCF-7,
Hs578T and PC-3 cell lines; suggesting that the transfected MT-3 protein retained its growth
inhibitory bioactivity first noted in the neural system [1,11,14]. The identical vector system has also
been utilized successfully to stably transfect the HK-2 cell line, an immortalized non-tumorigenic
cell culture model of the human renal proximal tubule [22]. In this study, the MT-3 stable
transfectants were shown to express both MT-3 mRNA and protein, and to regain the differentiated
property of vectorial active ion transport. The MT-3 protein has also been shown to be expressed in
situ in many of the epithelial cell types of the human kidney including those of the proximal tubule
[23]. In a current study using an immortalized, non-tumorigenic, cell culture model of human
urothelium (UROtsa cells), stable transfection with MT-3 has produced comparable findings to those
found using the MCF-10A cell line [D. Sens, personal communication]. Stable transfection of MT-3
into the UROtsa cell line was shown to result in MT-3 mRNA expression similar to that noted above
in the MCF-10A cells, but to result in no expresssion of the MT-3 protein. Similar to the human
breast, MT-3 has been shown to be overexpressed in bladder cancer, but to have no expression in the
normal human bladder urothelium [16]. Thus, the present study shows that MT-3 protein expression
is restricted in the MCF-10A cells stably transfected with the MT-3 coding sequence.
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One reason that the MCF-10A cells stably transfected with the MT-3 coding sequence would restrict
the expression of the MT-3 protein would be if such expression would be lethal or prevent cell
proliferation. Since stable transfection requires the clonal growth of the antibiotic resistant,
transfected cells from the original population, there is an obvious selection bias for cells that can
survive and proliferate in culture. In this regard, it is not unusual for attempts at stable transfection
to end with false positive colonies that have adapted to survive the selection procedure and that do
not express the transfected gene sequence. What is surprising in the present study, is that the stably
transfected MCF-10A cells express MT-3 mRNA and not protein; and that malignant breast cancer
cell lines show no such restriction, being able to express both MT-3 mRNA and protein under
identical transfection conditions. While there presently is no mechanistic explanation for these
findings or what might stabilize the expression of the MT-3 protein, one possible mechanism was
removed from consideration. It is well-documented from studies in rodents, and in cell lines derived
from rodent and human resources, that the MT-1 and MT-2 isoforms are stimulated by a wide
variety of factors and are primarily regulated at the level of transcription [24]. However, there is
recent evidence in rodents following treatment with Cu+2 and Cd+2 which shows that the MT-1 and
MT-2 protein levels can be regulated at the level of translation and that protein level often has no
clear relationship with the level of mRNA [25,26]. In these studies high tissue levels of MT-1 and
MT-2 mRNA expression were found to be unaccompanied by MT protein accumulation until the
cells were exposed to either Cu+2 and Cd+2, at which time there was a substantial accumulation of
MT protein without additional mRNA expression. An explanation for this finding was that metal
saturation of the MT protein stabilizes the MT protein against degradation. In the present study, the
treatment of the MT-3 transfected MCF-10A cells with both lethal and sub-lethal concentrations of
Cd+2 had no effect on MT-3 protein accumulation, even though this exposure did result in greatly
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elevated levels of the MT-1 and MT-2 proteins. This effectively rules out the possibility that MT-3
protein is not found in MCF-10A cells due to there being insufficient metal to saturate the MT-3
protein and thus prevent it from being rapidly degraded due to a lack of metal saturation. The
finding that MT-1 and MT-2 protein was induced by Cd+2 treatment also provides evidence that the
MCF-10A cells are able to accumulate Cd+2 from the external environment.

There exists only one study which has analyzed matched samples from cancer patients for both MT3 mRNA and protein expression. In this study, a retrospective analysis of MT-3 mRNA and protein
expression was performed on archival paraffin-embedded specimens of bladder cancer [16].
Immunohistochemistry was used to semi-quantify the MT-3 protein which it was found to be
unexpressed in the normal bladder and to have low intensity staining in low-grade bladder cancers,
moderate staining in high grade bladder cancers, and very intense staining in carcinoma in situ
(CIS), with QuickScore values of 1.29, 2.07 and 2.43 for the cancers, respectively. An analysis of
MT-3 mRNA on total RNA extracted from paraffin-embedded sections of the identical cancer
specimens demonstrated that MT-3 mRNA was present in all the cancers at the same relative levels
of expression when compared to the β-actin housekeeping gene. While both techniques can be
subject to substantial technical errors, the data provide initial evidence that post-transcriptional
regulation of MT-3 expression might also occur in in situ cancers. This would suggest that MT-3
expression could be a two-step process during progression, the first being the overexpression of MT3 mRNA which could be followed later by the overexpression of the MT-3 protein.
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HIGH CONSTITUTIVE EXPRESSION OF METALLOTHIONEIN ISOFORM 1 AND 2
mRNA, BUT NOT PROTEIN, IN NORMAL HUMAN BREAST EPITHELIAL CELLS
AND THE EFFECT OF CADMIUM EXPOSURE ON IMMORTALIZED HUMAN
BREAST CELL LINE, MCF-10A
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INTRODUCTION

In addition to their role in metal toxicology, an involvement of MT-1 and MT-2 in the development
of human breast cancer is suggested by numerous studies which show a correlation between MT-1/2
protein expression and breast cancer prognosis and progression. In an immunohistochemical
analysis of MT-1/2 expression in 86 cases of routinely fixed and paraffin-embedded primary breast
carcinomas, MT over-expression was found in the invasive components of 7 of 32 pT1 and 17 of 28
pT2 invasive ductal carcinomas, whereas all 26 invasive lobular carcinomas gave weak or negative
results [1]. Fourteen of 17 pT2 and 2 of 7 pT1 invasive ductal carcinomas with MT over-expression
developed metastases during follow-up with poor prognostic outcome. In contrast, only 3 of 11 pT2
and none of the 25 pT1 cases without MT over-expression had a poor clinical course. This
difference was found to be highly significant. This initial study concluded that MT over-expression
is associated with a significantly poorer prognosis, particularly in pT2 invasive ductal breast
carcinomas. These findings were confirmed and extended in a study employing 79 breast
carcinomas [2]. In this study, a statistically significant association was found between MT
immunostaining and histological grade as well as nuclear grade. An inverse relationship between
MT staining and estrogen receptor content of tumors was also demonstrated. A statistically
significant association was demonstrated between moderate and strong MT immunostaining and
decreased overall survival and shorter disease-free survival. MT immunostaining was also
predictive of a worse prognosis in the subgroup of lymph node-negative and estrogen receptornegative patients. These studies were further confirmed and augmented to include an analysis
showing that MT staining was also predictive of a poor prognosis in lymph node positive patients
[3].
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The expression of MT was also analyzed in normal breast tissue and in a variety of benign, preinvasive, and malignant breast lesions [4]. It was confirmed in this study that normal breast tissues
did not stain for MT. Also, of particular significance was the finding that in 12/24 ductal in situ
carcinomas and in 9/20 invasive ductal carcinomas there was MT over-expression; suggesting that
the in situ components within invasive ductal carcinomas generally reflected the MT status of their
invasive counterpart. It was concluded that breast carcinoma cases with MT over-expression arise
from lesions which also demonstrate MT over-expression and that MT over-expression in
carcinomas is a genuine feature of the tumor cells and not simply related to endogenous or
exogenous factors known to induce MT synthesis. This concept is in agreement with studies by
Douglas-Jones and coworkers [5] who analyzed MT expression in duct carcinoma in situ and found
MT over-expression to arise from early lesions which also over-express MT. Two other recent
studies confirm and reinforce these findings [6, 7]. A recent large study, with multiple prognostic
and proliferative markers in addition to MT, concludes that MT-1/2 immunoreactivity has potential
for use as a prognostic marker for breast cancer [8].

To effectively study the role of MT-1 and MT-2 expression in the development and progression of
breast cancer requires a cell culture model representative of the normal human breast epithelial cell.
The initial goal of the present study was to determine if the immortalized human breast epithelial
cell line, MCF-10A, could serve as an effective model to study the regulation of metallothionein
expression in the human breast epithelial cell.
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RESULTS

Basal Expression of MT-1 and MT-2 mRNA and Protein in MCF-10A Cells: Total RNA and
protein was isolated from confluent MCF-10A cells and used to determine the basal expression of
MT-1/2 protein and the MT isoform-specific mRNAs using RT-PCR as described previously [9, 10,
11]. Based on a total RNA input of 500 ng and 40 cycles of PCR there was no detectable expression
of mRNA representing the MT-1A, MT-1B, MT-1F, MT-1G, or MT-1H genes in MCF-10A cells
(Fig 14). In contrast, mRNAs representing the MT-1E, MT-1X, MT-2A and g3pdh genes were
expressed in MCF-10A cells based on identical total RNA inputs following 30, 22, 25 and 30 cycles
of PCR, respectively (Fig 14).

Figure 14. RT-PCR assay showing of MT-1A, -1B, -1E, -1F, -1G, -1H, -1X, -2A and
glyceraldehyde 3-phosphate dehydrogenase (g3pdh) mRNA in MCF-10A cells. No expression
was detected at 40 cycles of PCR in reactions containing 500 ng of total RNA for MT-1A, -1B, -1F, 1G and -1H. In contrast, MT-1E, -1X, -2A and g3pdh mRNAs were detected at 30, 22, 25 and 30
cycles of PCR, respectively. The last two lanes representing the negative controls for the RT-PCR
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reactions include a non-template control (C1) where water was added instead of the RNA and noreverse-transcriptase control (C2) where water was added instead of enzyme.

Based upon the IOD of g3pdh at 30 cycles and MT-1E at 40 cycles, MT-1X at 30 cycles and MT-2A
at 35 cycles, the relative abundance (IOD of the specific isoform/IOD of g3pdh) of each MT mRNA
was 0.72 for 1E, 0.57 for 1X, and 0.45 for MT-2A (Fig. 15 A, B, C) Immuno-blotting with an MT
antibody that recognizes both the MT-1 and MT-2 isoforms, but not the other isoforms of MT,
demonstrated that the MCF-10A cells expressed 3.3 ± 0.6 ng (n = 6) of MT-1/2 protein/µg total cell
protein (Fig. 15 D).
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Figure 15. Relative expression of MT-1E, -1X and -2A mRNA, and Protein in two samples
(sample A and Sample B) of human breast tissue and MCF-10A cells compared with the g3pdh
house keeping gene. (A) Relative expression of MT-1E mRNA. (B) Relative expression of MT-1X
mRNA. (C) Relative expression of MT-2A mRNA. (D) MT-1/2 protein levels in two samples of human
breast tissue and MCF-10A cells.

Basal Expression of MT-1 and MT-2 mRNA and Protein in Human Breast Tissue and MT-1
and MT-2 mRNA in Microdissected Breast Duct Epithelial Cells: Total RNA and protein were
prepared from human breast tissue obtained from two cases of elective reduction surgeries. The
tissue was dissected free from attached fat prior to the isolation of total RNA and protein based on
the different textures and colors of the tissue types. Fatty tissue was identified as gelatinous and
yellow while the ductal tissue was identified as firm and tan. Using a total RNA input of 500 ng and
40 cycles of PCR it was demonstrated that there was no expression of mRNA representing the MT1A, MT-1B, MT-1F, MT-1G, and MT-1H genes in both samples of the human breast tissue (data not
shown). Using an identical total RNA input, it was demonstrated that mRNAs for MT-1E, MT-1X,
MT-2A and g3pdh genes were detectable in both samples of human breast tissue at 40, 30, 35, and
30 PCR cycles, respectively (Fig 16). To allow a comparison to the MCF-10A cell line, the
expression of MT-1E, MT-1X and MT-2A was expressed relative to g3pdh at identical cycle
numbers to that described above for MCF-10A cells. On this basis, it was demonstrated that MT-1X
mRNA was expressed at a level approximately twice that found in MCF-10A cells; MT-2A mRNA
at a level approximately equal to that found in MCF-10A cells; and, MT-1E at a level approximately
one-half than that found in MCF-10A cells (Fig. 15 A, B, C). The level of MT-1/2 protein in each of
the human breast samples was also determined and found to be 1.1 ± 0.2 and 1.2 ± 0.3 of MT-1/2
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protein/µg total cell protein (Fig. 15 D).

Figure 16. Accumulation of MT-1E, -1X, -2A and glyceraldehyde 3-phosphate dehydrogenase
(g3pdh) mRNA in two samples of human breast tissue (A and B) and MCF-10A (M) cells.
Using 500 ng of total RNA input, MT-1E, -1X, -2A and g3pdh mRNA were detected at 40, 30, 35
and 30 PCR cycles of PCR, respectively. Negative controls represent the RT-PCR reactions include
a non-template control (C1) where water was added instead of the RNA and no-reversetranscriptase control (C2) where water was added instead of enzyme.

The expression of MT-1X and MT-2A mRNA was also determined on two samples of normal breast
duct epithelial cells enriched from surrounding stromal and vascular cells using the technique of
laser capture microdissection. This analysis was performed to gain further evidence that the MTisoform mRNAs were present in the duct epithelial cells. For this analysis, total RNA was prepared
from ducts isolated from full-thickness (5 micron) paraffin-embedded breast tissue sections
following laser capture microdissection (Fig 17 A, B).
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Figure 17. Microdissection of ductal epithelial cells from normal breast tissue. (A) Five micron
thick section of paraffin-embedded normal breast tissue was stained lightly with hematoxylin and
eosin before laser capture. (B) Tissue section shown is after laser capture microdissection.

The RT-PCR was performed as described above, except a primer pair for the β-actin housekeeping
gene producing a 194 bp product was also included in the analysis. The β-actin primer pair provided
a more appropriate control to the analysis since the PCR product is similar in size to the MT PCR
reaction products. The g3pdh PCR product is much larger than the MT isoform mRNA reaction
products and it has been reported that total RNA from formalin-fixed, paraffin-embedded tissue
yields a higher proportion of fragmented RNA relative to intact RNA that does than fresh tissue [12].
Laser captured microdissection technique also failed to detect MT-1E mRNA from parafin
embedded slides at 40 cycle PCR while RT-PCR analysis of fresh breast mRNA at 40 cycle yield
MT-1E mRNA message. The results of the analysis of total RNA isolated from the two samples of
microdissected duct cells demonstrated the expression of MT-1X and MT-2A in the ductal epithelial
cells (Fig 18). MT protein could not be determined since protein cannot be extracted from formalinfixed tissue.
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Figure 18. Basal expression of MT-1X and MT-2A in normal human breast. Bands representing
RT-PCR products for β-actin (194 bp), MT-1X (151 bp) and MT-2A (259 bp) after 40 cycle PCR.

Expression of MT-1/2 Protein and MT-Isoform Specific mRNAs When MCF-10A Cells are
Exposed to Lethal and Sublethal Levels of Cd+2: The above results demonstrated that both the in
situ normal breast epithelial cells and the MCF-10A cells expressed abundant amounts of MT
mRNA, but only a very modest amount of MT-1/2 protein. Since Cd+2 is bound to the MT protein
with high affinity and is an inducer of MT gene transcription in most mammalian cell systems,
studies were designed to determine what effect Cd+2 exposure would have on the accumulation of
MT mRNA and protein in the MCF-10A cells. This was accomplished by determining the
expression of the MT-1 and MT-2 isoform-specific mRNAs and MT-1/2 protein when the MCF-10A
cells were exposed to CdCl2 over a short-term (48 h) and extended (16 day) time course. Four
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concentrations of CdCl2 were utilized: 3 µM which produced no cell death over the 16 day time
course; intermediate concentrations of 7 µM and 15 µM, which produced approximately 50% cell
death over the 16 day time course; and, 30 µM which produced significant levels of cell death
midway in the 16 day time course (Fig 19). The respective mRNA and proteins were determined at
4, 8, 12, 24 and 48 h for the short-term time course and at 1, 2, 4, 7, 10, 13 and 16 days for the
extended time course. The expression of MT mRNA was normalized to a control value of 1.0 for
data presentation. For each of the respective MT mRNAs analyzed there was no significant
difference in the expression levels of the 48 h and 16 day time courses over the control cells (data
not shown). The RT-PCR analysis of MT-isoform-specific MT-1 and MT-2 mRNAs at 500 ng total
RNA inputs and 40 reaction cycles demonstrated no expression of the MT-1A, MT-1B, MT-1F, MT1G, or MT-1H mRNA at any point in the time course (data not shown).

Figure 19. Viability of MCF-10 cells exposed to CdCl2. The MCF-10 cells were exposed to 0 µM
(), 3µM ( ), 7 µM (S), 15 µM (|) and 30 µM () of CdCl2 for 16 days of extended time course.
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Cell viability was determined by automated counting of DAPI-stained nuclei and all determinations
were in triplicate. Values shown are the percentages of the mean cell numbers at each time point
divided by the mean cell numbers of the control cells for each triplicate determination.

Analysis of the MCF-10A cells exposed to 7, 15 or 30 µM Cd+2 for 48 h demonstrated that there was
no significant increase in MT-1X or MT-2 mRNA and a significant increase in MT-1E mRNA at
only 3 of the 21 points of acute time course (Fig 20 A, B, C). In contrast, the corresponding analysis
of MT-1/2 protein expression demonstrated that following 24 h of Cd+2 exposure, there were
significant increases in MT-1/2 protein at all three levels of Cd+2 exposure (Fig 20 D). The level of
MT-1/2 protein showed a significant increase with increasing time of exposure between 24 and 48 h,
but there was not a dose response as judged by there being no significant difference (p > .05) in
accumulation due to the level of exposure to Cd+2 at either the 24, 36 or 48 h time points.
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Figure 20. Relative expression of MT-1E, -1X, -2A mRNA, and MT 1/2 protein levels in MCF10A cells after short-term exposure to CdCl2. MCF-10 cells were exposed to 7µM (grey bars), 15

µM (white bars), and 30 µM (black bars) CdCl2 for 48 hrs. The expression of MT-1E, MT-1X and
MT-2A mRNA is shown relative to that of the g3pdh housekeeping gene and then normalized to a
control value of 1.0. The determinations were performed in triplicate.
Exposure of the MCF-10A cells to 3 µM Cd+2 for 16 days demonstrated no increase in the
expression of mRNAs for the MT-1E, MT-1X and MT-2A genes (Fig 21 A, B, C). An increase in
exposure level to 7 µM Cd+2 for 16 days produced no increase in MT-1X mRNA and a modest, but
significant increase in MT-2A mRNA on days 13 and 16 and of MT-1E mRNA on day 4 and 10 of
the time course. A further increase in exposure level to 15 µM Cd+2 resulted in a significant increase
in MT-1X on day 2; MT-2A on days 10, 13 and 16; and, MT-1E on days 4 and 13. These increases
were approximately 2-fold over control. The highest level of Cd+2 exposure (30 µM) which was
100% lethal to the cells by day 7 of the time course produced no significant increase in MT-2A
mRNA and a significant increase in MT-1E and 1X on day 2. There was no evidence of a dose
response between mRNA expression of the MT-2A, MT-1X or MT-1E genes and Cd+2 level. In
contrast, the level of MT-1/2 protein was significantly increased at all levels of Cd+2 exposure by
day 4 of the time course (Fig 21D). The MT-1/2 protein level at the lowest level of Cd+2 exposure
that produced no cell lethality over the 16 day time course, increased from 4 to 37 ng/µg total protein
by day 16 of exposure. There was an incremental increase in MT-1/2 protein at day 4, 7 and 10 with
a plateau at day 10 through 16. A similar pattern of MT-1/2 protein accumulation occurred at the 7
and 15 µM levels of Cd+2 exposure, except the increase and plateau occurred earlier in the time
course (day 2 and 7, respectively) and levels of accumulation were approximately 2-fold higher (5
to 6% of total cell protein). There was no evidence of a dose response between MT-1/2 protein
expression and level of Cd+2 exposure.
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Figure 21. Relative expression of MT-1E, -1X, -2A mRNA, and MT 1/2 protein levels in MCF10A cells after long-term exposure to 3 µM, 7 µM, 15 µM and 30 µM of CdCl2. MCF-10 cells
were exposed to 3 µM (striped bars) 7µM (grey bars), 15 µM (white bars), and 30 µM (black bars)
CdCl2 for 48 hrs. The expression of MT-1E, MT-1X and MT-2A mRNA is shown relative to that of
the g3pdh housekeeping gene and then normalized to a control value of 1.0. The determinations
were performed in triplicate.

DISCUSSION

The initial goal of this study was to determine if the immortalized, but non-tumorigenic, MCF-10A
human breast epithelial cell line could serve as a model to study the dysregulation of MT in human
breast cancer. The need for a model of the breast epithelial cell that recapitulates the in situ
expression pattern of the first and second isoforms of MT is based on the wealth of information
showing MT-1/2 expression is altered in patients with breast cancer. In retrospective patient-based
studies it has been shown that the overexpression of MT-1/2 in breast cancer is associated with a
poor prognosis [1, 2, 3, 6, 13, 14]; higher histological grade of the tumor [2, 5, 14, 15]; estrogen
receptor status [2, 3, 7, 8]; and lymph node involvement [3, 16]. MT measurement these studies was
based on an antibody that recognizes both the MT-1 and MT-2 isoforms of the MT gene family, but
not the MT-3 and MT-4 isoform family members [17]. In all these studies, normal breast epithelium
did not react with MT-1/2 antibody. As such, the first investigation of the MCF-10A cells was to
determine if the expression of MT-1/2 protein was similar to that found in tissue obtained from the
normal human breast. The MCF-10A cells were found to express approximately 3.3 ng of MT-1/2
protein/µg total protein compared with 1.15 ng of MT-1/2 from normal breast tissue. These levels of
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expression are in good agreement with one another, and are in even closer agreement when
consideration is given to the fact that the in situ sample would be contaminated with stromal and
vascular cell types. Thus, the basal expression of the MT-1/2 protein is one indication that the
MCF-10A cell line might model MT expression in the normal breast epithelial cell.

The expression of the human MT-1 and MT-2 isoform proteins is theoretically supported by seven
active MT-1 genes and one active MT-2 gene; designated as MT-1A, MT-1B, MT-1E, MT-1F, MT1G, MT-1H, MT-1X and MT-2A [18, 19]. The expression of these genes has not been previously
determined in the normal breast epithelial cell or the MCF-10A cell line. The MCF-10A cells were
found to express no mRNA for the MT-1A, MT-1B, MT-1F, MT-1G and MT-1H genes, but did
express mRNA for the MT-1E, MT-1X and MT-2A genes. The MT-1X, MT-2A and MT-1E were
found to be very abundant transcripts and in large excess to what would be expected for the
accumulation of the low amount of MT-1/2 protein (3.3 ng/µg total protein) that was found in MCF10A cells. The major reason for concluding that MT-1/2 mRNA was in large excess over that
needed to support MT-1/2 protein accumulation was the fact that transcripts for MT-1X were
detected at 22 cycles, MT-2A at 25 cycles and MT-1E at 30 cycles of PCR. With a total RNA input
of 500 ng these cycle levels are indicative of very abundant transcripts and the levels were much
more abundant than that of mRNA from the g3pdh housekeeping gene, which was detected at 30
cycles. Furthermore, amounts of MT-1X, -1E, -2A and g3phd mRNAs are probably underestimated
due to the use of higher temperatures required for the MT RT-PCR reactions; a condition necessary
to assure primer specificity among the highly homologous MT isoforms [11]. This finding
generated initial concern that the MCF-10A cells might have inappropriate MT mRNA expression
and be compromised as a model system. While it is difficult to predict with certainty the amount of
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mRNA necessary to support the synthesis of a given amount of any protein, the concern that MCF10A cells might have inappropriately overexpressed MT-1 and MT-2 mRNA was alleviated when
MT-1 and MT-2 mRNA was analyzed in normal breast tissue. Normal breast tissue also expressed
mRNA for the MT-1E, MT-1X and MT-2A genes at levels similar to that of the MCF-10A cell line.
Laser capture microdissection was used to further support that this expression originated from
ductal epithelial cells. Thus, it was demonstrated that the MCF-10A cell line has basal expression of
the MT-1 and MT-2 mRNA isoforms similar to that of the in situ breast epithelial cell.

It is well-documented from studies with rodents, and in cell lines derived from rodent and human
sources, that MT-1 and MT-2 are stimulated by a wide variety of factors and are primarily regulated
at the level of transcription [20]. However, there is recent evidence in rodents following treatment
with Cu+2 and Cd+2 which shows that MT protein levels can be regulated at the level of translation
and that protein level often has no clear relationship with mRNA levels [21]. To determine if the
high levels of basal MT-1 and MT-2 mRNA found in MCF-10A cells might be evidence for
translational regulation of MT-1/2 protein accumulation, the MCF-10A cells were exposed to lethal
and sub-lethal levels of Cd+2 under both acute and extended periods of exposure. Cadmium is a
metal pollutant that binds MT with high affinity and is a classic inducer of MT transcription [19, 22].
For the MCF-10A cells, it was demonstrated that Cd+2 elicited only a marginal increase in MT-1E,
MT-1X or MT-2A mRNA abundance at either lethal or sub-lethal levels of exposure under both
acute and extended periods of exposure. However, Cd+2 exposure did result in a large increase in
MT-1/2 protein under identical conditions, reaching levels of 6% of total cell protein following
extended exposure to Cd+2. The only other organ that has been examined in a manner similar to that
of the human breast is the human bladder urothelium. The in situ human bladder was shown to
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express no MT-1/2 protein, but to have expression of the MT-1E, MT-1X, and MT-2A mRNAs,
with each mRNA level being substantially less than that of the breast [23]. A human immortalized,
but non-tumorigenic cell line (UROtsa), was shown to have a similar expression of the MT-1E, MT1X and MT-2A genes and MT-1/2 protein as that of human urothelium [24]. Treatment of the
UROtsa cell line with Cd+2 under similar conditions to that of the MCF-10A cells resulted in only a
modest increase in the MT mRNAs and an intermediate increase in MT-1/2 protein; a result
suggesting that both transcriptional and post-transcriptional regulation could be a factor in the
human bladder [25]. The present findings with the MCF-10A cells are strong evidence that
translational regulation could be a major mechanism in determining MT-1/2 protein levels in human
breast epithelial cells.

The finding that Cd+2 might increase MT-1/2 protein accumulation in MCF-10A cells through a
post-transcriptional mechanism is interesting in light of the study from Finland which demonstrated
an association between human breast concentrations of Cd+2 and breast cancer [26].

One

consequence of a Cd+2-mediated post-transcriptional accumulation of MT-1/2 protein that would be
consistent with development of a cancer cell phenotype would be increased resistance of the cell to
programmed cell death. Studies of cells from MT-null mice have provided direct evidence that MT
expression prevents apoptosis [27], and studies in the MCF-7 breast cancer cell line have shown that
the antisense down-regulation of MT-1/2 expression in the malignant breast epithelial cell increases
sensitivity to apoptosis [28]. Generating further interest in Cd+2 exposure and breast cancer is the
recent study that demonstrates estrogen receptor positive, p53 positive, breast cancer cell lines
accumulate higher levels of MT-1/2 protein when exposed to Cd+2 than estrogen receptor negative,
p53 negative, breast cancer cell lines [29]. There is also evidence that MT-1E gene expression is
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altered at the level of transcription in human breast cancer. In a study of 4 breast cancer cell lines,
MT-1E mRNA was highly expressed in 2 estrogen receptor negative cell lines (MCF-7 and T-47D),
but absent in the 2 estrogen receptor positive cell lines (Hs578T and MDA-MB-231) [9]. Increased
expression of MT-1E mRNA correlated with increased MT-1/2 protein expression [9]. This cell
culture-defined relationship was confirmed in a study of fresh, surgically removed breast cancer
tissue in which it was shown that MT-1E mRNA was highly expressed in estrogen receptor-negative
human invasive ductal breast cancers compared to estrogen receptor-positive tumors [30]. The
MCF-10A cell line should be helpful in determining the changes that occur in the regulation and
expression of the MT-1 and MT-2 isoforms between the normal and malignant breast epithelial cell.
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Dulbecco’s Modified Eagle Medium (DMEM)

Low glucose DMEM (Gibco-BRL, Rockville, MD., Cat No. 31600-75) with L- glutamine and
sodium pyruvate (100 mg/ml) but without sodium bicarbonate, was stored in powdered form at
40 C. To make 5 liters of DMEM, 49.9 gr of powder DMEM was dissolved in 4,950 ml of sterile
water in a 6 liter flask by constantly stirring. Fifty ml of Penicillin/Streptomycin (Gibco-BRL,
Cat No. 15140-122), 5 ml of Fungizone™ (Gibco-BRL, Cat No. 15295-017) and 18.5 gr of
sodium bicarbonate (Gibco-BRL, Cat No. 11810-033) were added to the 4,950 ml solution. The
solution was stirred for 45 minutes at room temperature. Then the solutions was filtered using
0,22 µm Acrocap™ filters (Gelman Laboratory, Ann Arbor, MI, USA. Cat. No. PN4480).
Filtered medium was stored in 500 ml aliquots at 40 C for up to three weeks.

Ham’s F-12 Nutrient Mixture

Ham’s F-12 Nutrient Mixture (Gibco-BRL, Cat No. 21700-109) with L-glutamine, but without
sodium bicarbonate, was stored in powdered form at 40 C. To make 5 liters of F-12 Medium,
53.1 gr of powder Ham’s F-12 was dissolved in 4,945 ml of sterile water in a 6 liter flask by
constantly stirring. Fifty ml of Penicillin/Streptomycin (Gibco-BRL, Cat No. 15140-122), 5 ml
of Fungizone™ (Gibco-BRL, Cat No. 15295-017) and 5.88 gr of sodium bicarbonate (GibcoBRL, Cat No. 11810-033) were added to the 4,945 ml solution. The solution was stirred for 45
minutes at room temperature. Then the solution was filtered usin 0.22 µm Acrocap™ (Gelman
Laboratory, Ann Arbor, MI, USA. Cat. No. PN4480) filter. Filtered medium was stored in 500
ml aliquots at 40 C for up to three weeks.
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Phosphate Buffer Saline (1 x PBS)

To make 5 liters of 1 x PBS, 42.5 gr of NaCl (Sigma, Cat No. S-9888) was combined with 0.6 gr
of Na2HPO4 (Fisher Scientific, Fair Lawn, NJ, USA. Cat No.S-374) and 0.12 gr NaH2PO4 (Fisher
Scientific, Cat No.S-369) in a total volume of 5 liters of sterile water. PBS was aliquoted into
500 ml bottles and autoclaved. PBS was stored up to a month at 40 C.

Breast Cancer Cell Line Medium

MCF-7, T-47D, Hs578T and MDA-MB-231 cell lines were maintained in DMEM supplemented
with 5% Fetal Calf Serum (Hyclone, Logan, UT, Cat No. SH30070.03)

and 5mg/ml Glucose

(Dextrose, Fisher, Fair Lawn, NJ Cat No. D16-500). Glucose was reconstituted in sterile water.

Immortalized Normal Breast Cell Line, MCF-10 Medium

MCF-10 cell line was maintained in 1:1 mixture of Ham’s F-12 medium and DMEM
supplemented with 5% (v/v) fetal calf serum (Hyclone, Logan, UT, Cat No. SH30070.03), 10
µg/ml insulin (Sigma Inc, St. Louis, MO, Cat No. 58H0375), 0.5 µg/ml hydrocortisone (Sigma
Inc, St. Louis, MO, Cat No. 101K8925), 20 ng/ml epidermal growth factor (Invitrogen Life
Technologies, Cat No 13247-051), 0.1 µg/ml cholera toxin(Sigma Inc, St. Louis, MO, Cat No.
MFCD00212923). All the reagents were reconstituted in sterile water.
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GENE

VENDOR

CONC.

SEQUENCE

CONC.

UPPER PRIMER

GA3PDH

CLONETE

(983 BP)

CATNO.54

0.1UM

5’TGAAGGTCGGTGT

SEQUENCE
LOWER PRIMER

0.1UM

GAACGGATTTGGC3’

5’CATGTAGGCCATG
AGGTCCACCAC3’

06
MT-1A

Gibco-BRL

0.1uM

(219 bp)
MT-1B

Gibco-BRL

0.1uM

Gibco-BRL

0.1uM

Gibco-BRL

0.1uM

Gibco-BRL

0.1uM

0.1uM

(315 bp)
MT-1X

Gibco-BRL

0.4uM

Gibco-BRL

0.1uM

(259 bp)
MT-3

Gibco-BRL

0.1uM

(325 bp)
MT-4
(213 bp)

0.1uM

5’AGTCTCTCCTCGGC

5’CTTCTCGCTTGGGA

5’CCTCTTCTCTTCTC

5’TCTCCTTGCCTCGA

0.1uM

0.1uM

5’ACATCTCTGGGAG
AAAGGTTGGTC3’

0.1uM

5’AGGGGTCAAGATT
GTAGCAAA3’

0.1uM

5’GCAAATGAGTCGG
AGTTGTAG3’

0.4uM

5’GGGCACACTTGGC

AATGGAC3’

ACAGC3’

5’CCGACTCTAGCCGC 0.1uM

5’GTGGAAGTCGCGT

CTCTT3’

TCTTTACA3’

5’CCGTTCACCGCCTC

0.1uM

CAG3’
Gibco-BRL

5’CAGGTTGTGCAGG
TTGTTCTA3’

GCTTGG3’

(151 bp)
MT-2A

5’GCTTGTTCGTCTCA

ACTCTA3’
Gibco-BRL

5’AGACAAACCGGTC
AGGTAGTT3’

TTTGC3’

(309 bp)
MT-1H

0.1uM

CTGGTG3’

(232 bp)
MT-1G

5’GCTTGTCTTGGCTC

5’ATATCTTCGAGCAG
GGCTGTC3’

CACA3’

(284 bp)
MT-1F

0.1uM

CCAACT3’

(287 bp)
MT-1E

5’CTCGAAATGGACC

5’CACCAGCCACACTT
CACCACA3’

5’CATGGACCCCAGG
GAATGTGT3’
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0.1uM

5’GGGGTGGGCACGA
TGGA3’

Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) primer pairs were obtained from
Clonetech (Palo Alto, CA, USA). The selection of metallothionein primer pairs for RT-PCR was
described by Mididoddi et al. (1996) Toxicol Lett. 85(1):17-27).

PCR Product
Clontec GA3PDH

Denaturation
0

95 for 2 min

Optimal Cycles
0

95 C for 30 sec

Optimal Cycles
25 and 30 cycles

680C for 30 sec
Metallothionein
1A, 1B, 1F, 1G

950 C for 2 min

1E, 1X, 2A

30, 35, 40 cycles

680 C for 30 sec

1H, MT-3, MT-4
Metallothionein

950 C for 30 sec

950 C for 2 min

950 C for 30 sec
0

68 C for 30 sec
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ANTIBODIES FOR THE DETECTION OF METALLOTHIONEIN PROTEINS
MT 1/2, E9 Antibody (1:1000 dilution), Primary Antibody
4,5 ml of 10% BSA, 225 µl of 4% NaN3, 450 µl of E9 MT 1/2 antibody (Dako Corp.,
Carpinteria, CA, Cat No. Mo639), 1 x PBS to 45 ml.

Anti-Mouse IgG Antibody (1:500 dilution), Secondary Antibody
1.8 ml of 10 % BSA, 225 µl of 4% NaN3, 90 µl of antibody (1µg/ml) (Promega, Cat No.
S372B), 1 x PBS to 45 ml.

MT-3 Polyclonal Antibody (1:100 dilution), Primary Antibody
9 ml of 10% BSA, 225 µl of 4% NaN3, 112.5 µl of 2 µg/µl metallothionein 3 anti-rabbit
antibody, 1 x PBS to 45 ml. The synthesis of the metallothionein 3 anti-rabbit antibody has been
described previously (Garrett, et al. (1999) Toxicol Lett. 105(3):207-214). New Zeland White
rabbits were immunized with a peptide (GGEAAEAEAEKC) corresponding to MT-3 amino
acids 53-64 that contain the MT-3 unique amino acid insert. The dodeca-peptide was conjugated
through the C-terminal sulfhyryl group to keyhole limpet hemocyanine using maleimidobenzoylN-hydrosuccinimide ester. The MT-3 antibody was affinity purified using the dodecapeptide
linked to a SulfoLink gel (Pierce, Rockford, IL) through the C-terminal cysteine residue. The
MT-3 antibody has been shown to selectively bind to both tissue sections (immunohistochemical
localization) and protein extracts (Western blot analysis) of human brain.

Anti-Rabbit Antibody (1:500 dilutions), Secondary Antibody
1.8 µl of 10 % BSA, 225 µl of 4% NaN3, 90 ul of 1 µg/ml anti-rabbit antibody (Promega, Cat
No. S3831), 1 x PBS to 45 ml.
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ALKALINE PHOSPHATASE BUFFER

Alkaline phosphatase buffer for use with the Vectastin ABC-AP detection kit (Vector
Laboratories, Burlingame, CA, USA) was a solution of 100 mM Tris-HCl at pH 8.2.

TRIS HARVESTING BUFFER

The cells were harvested in 100 mM Tris-HCl,10 mM DDT at pH 8.2 for immuno-blot protein
analysis.

CRYSTAL VIOLATE
Solution A: Crystal Violate
Ethyl Alcohol (95%)

2 gr.
20 ml

Solution B: Ammonium Oxalate
Distelled water

0.8 gr.
80.0 ml

The solutiona A and B were mixed. Then, it was filtered through a filter paper into a staining
bottle. The solution was stored 24 hours before use.
3% GLUTARALDEHYDE

Four ml of 50 % glutaraldehyde (Sigma, St Louis, MO 63178) were mixed with 96 ml of ditelled
water. The solution was stored at 4 0 C for up to six months.
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